CONGRESS - European Renal Association

59TH

ERACONGRESSPARIS & VIRTUAL

MAY 19-22, 2022

FINAL PROGRAMME

2

CONGRESS INFORMATION

Please click on the links below to see the content.

> GENERAL INFORMATION

> OPENING HOURS

> IMPORTANT ADDRESSES

> ERA COUNCIL MEMBERS

> CONGRESS SCIENTIFIC COMMITTEE

> PAPER SELECTION COMMITTEE & ABSTRACTS REVIEWERS

> BEST ABSTRACTS

Ten best abstracts

Eight best abstracts presented by young authors

Best abstracts presented by young authors

59TH


MAY 19-22, 2022

https://www.era-online.org/en/paris2022/congress-information/

https://www.era-online.org/en/paris2022/opening-hours/

https://www.era-online.org/en/paris2022/important-addresses/

https://www.era-online.org/en/council-members/

https://www.era-online.org/en/paris2022/scientific-committee/

https://www.era-online.org/en/paris2022/paper-selection-committee-abstracts-reviewers/

https://www.era-online.org/en/paris2022/best-abstracts-travel-grants/

3

59TH


MAY 19-22, 2022

Dear Colleagues, dear Friends,The ERA Congress returns on site in 2022 after two years of fully virtual meetings due to the restrictions imposed by the Covid 19 pandemic. This year, the Congress will be hybrid with delegates in Paris or connected from their home Countries. This option will allow all participants to attend one of the best medical Congresses in Europe, in whichever way they prefer.The motto chosen for this year’s meeting is “Innovation, Prevention, Preparedness” that could summarise what we have learned from the “Cov19 era”.

Innovation, because medicine, particularly nephrology, needs constant innovation including new treatments and diagnostic tools. Prevention, since it is essential to develop early detection based on new screening methodologies, and more effective and personalized therapies.Preparedness, as we need to be prepared to face all kinds of possible new problems such as new pandemics, influx of patients fleeing their country due to unstable political situations and the resulting burden for health policy in a global world.

We constantly keep an eye on equity and ethics, as attested by the Welcome Lecture that will be presented by Valerie Luyckx on May 19, entitled “Equity, sustainability, and ethics in kidney health”. This outstanding contribution will open the 59th ERA Congress during the Welcome Ceremony.The Scientific Committee, chaired by Annette Bruchfeld, worked very hard to provide the best programme taking also into consideration gender balance, with fifty percent of invited speakers being female. She was supported by Maria José Soler, who acted as the Chair of the Paper Selection Committee and by the Congress President, Pierre Ronco as well as by the two Congress Secretaries, Denis Fouque and Ziad Massy. Signs of return to normality can also be seen from the large number of high-quality abstracts received from 76 countries. The final version of the programme is the result of many hours of coordinated hard work among the Scientific Committee Chair, the Congress President, the Paper Selecting Committee Chair, the Congress Secretaries and last but not least all the ERA Headquarter Staff. A special thanks goes to the new staff members, Manuela Lorusso, David Simon, Federica Lo Cascio and Gaston Chauchard.On May 19, the first day of the Congress, in addition to the traditional CME and Hands-On Courses, a new Hands-On Course on Renal Biopsy will be held. These tailored courses given by top European experts in the field and fully included in the Congress fee, will offer a unique opportunity for professional development. Another novelty this year are the Young Investigators Awards which from one have become three: the Rosanna Gusmano Award (for young investigators in basic science), the Stanley Shaldon Award (for young investigators in translational science) and the Eberhard Ritz Award (for young investigators in clinical science). For the first time, these excellent young investigators will be offered the opportunity to present their research topic in dedicated Plenary Lecture on May 22.The programme will also include three new sessions: on-site Moderated Mini-Orals, Quick Fire 1, 2, 3 and the Fishbowl Round Table.These three sessions will be held in the Mini-Orals Hall in a very dynamic way.Finally, the programme will be complemented by various interesting Industry Symposia.We also would like to welcome all ERA Members to the ERA General Assembly, where our President and the Ex-Officio Officers will update you on the work that has been done by our Society during the last year.The hybrid format of the Congress will not only offer educational activities and top scientific content, but also innovative networking opportunities: a new digital platform will enable all participants, including those who will be connected virtually, to actively contribute to group discussions based on specific topics and communicate with other delegates on our Social Media Wall. All delegates will be able to choose their favourite networking tools and join our international Community, sharing their knowledge and experience.

We are looking forward to welcoming you to the 59th ERA Congress!

WELCOMEADDRESS

Pierre Ronco, Congress President

Christoph WannerERA President

https://www.era-online.org/en/about-era/group-staff/era-operative-headquarters/

4

CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

MODERATED MINI-ORALS &

QUICK FIRE 1,2,3

INDUSTRY SPONSORED SYMPOSIA

THURSDAY - MAY 19, 2022 6

FRIDAY - MAY 20, 2022 13

SATURDAY - MAY 21, 2022 30

SUNDAY - MAY 22, 2022 47

FRIDAY - MAY 20, 2022 53


FRIDAY - MAY 20, 2022 59


59TH


MAY 19-22, 2022

59TH


MAY 19-22, 2022

Mini-Oral Sessions

Short pre-recorded presentations summarizing the accepted abstracts in 5 minutes

6

19THU

59TH


MAY 19-22, 2022

DAY AT A GLANCE

CONGRESS OPENING 7

PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES 7

HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD 7

CKD AND BONE MINERAL DISORDERS IN CKD 7

HAEMO AND PERITONEAL DIALYSIS 8

HANDS-ON COURSE ON RENAL BIOPSY 8

HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA 8

HANDS-ON COURSE ON CATHETER PLACEMENT 8

KIDNEY TRANSPLANTATION 9

BASICS OF GENETICS FOR NEPHROLOGIST 9

ACUTE KIDNEY INJURY 9

ELECTROLYTES AND UROLITHIASIS 9

HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA 10

HANDS-ON COURSE ON CATHETER PLACEMENT 10

WELCOME CEREMONY + WELCOME LECTURE 11

CME & HANDS-ON COURSESCONTENT &

DAILY INDEXSCIENTIFIC PROGRAMME


FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

59TH


MAY 19-22, 2022

7

19 T

HU

THUS C I E N T I F I C P R O G R A M M E19

HALL N03 08:45-12:20 (CEST)

CME 3 CKD AND BONE MINERALDISORDERS IN CKD

Chairs: Hanne Skou Jorgensen, DenmarkSandro Mazzaferro, ItalyJelmer Humalda, Netherlands

Introduction - setting the stage.Hanne Skou Jørgensen, DK

1 Bone loss in the era of steroid-sparing immunosuppressive protocols.

Martine Cohen-Solal, France

2 Renal osteodystrophy post-transplant – lessons from bone biopsy studies.

Nathalie Bravenboer, Netherlands

3 Mineral metabolism and acid-base disturbances.

Jelmer Humalda, Netherlands

4 Optimizing cardiovascular health post- transplant.

Marc Vervloet, Netherlands

5 Optimizing bone health post-transplant. Pieter Evenepoel, Belgium

Summary and concluding remarks.Sandro Mazzaferro, Italy

HALL N02 08:45-12:20 (CEST)

CME 2 HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD

Chairs: Beatriz Fernandez Fernandez, SpainPantelis Sarafidis, Greece Amaryllis Van Craenenbroeck, Belgium

A) CVD in CKD: Diagnosis1 Cardiovascular risk screening in CKD: biomarkers, cardiac MRI, cardiac US. Patrick Mark, United Kingdom

2 Cardiovascular risk screening in CKD: blood pressure monitoring. Michael Doumas, Greece

3 Cardiovascular risk screening in CKD: endothelial function (methods) and arterial stiffness. Marietta Theodorakopoulou, Greece

B) CVD in CKD: Treatment1 HF with pEF in CKD: the cardiology perspective... Anne-Catherine Pouleur, France

2 HF with pEFIN CKD: the nephrology perspective. Jolanta Malyszko, Poland

3 The role of lifestyle, exercise and rehabilitation in cardiorenal patient. Sharlene Greenwood, United Kingdom

C) CVD in CKD: CollaborationPerspectivesAchieving the best strategy for ESRD patients creating combined cardiorenal units.Jose Luis Gorriz, Spain

HALL N01 08:45-12:20 (CEST)

CME 1 PRIMARY & SECONDARYGN, VASCULITIS ANDAUTOIMMUNE DISEASES

Chairs: Annette Bruchfeld, SwedenKerstin Amann, GermanyAndreas Kronbichler, United Kingdom

1 Technical Challenges to Discover Novel Antigens and Autoantibodies in Minimal Change Disease and Membranous Nephropathy.

Astrid Weins, USA

2 Immunosuppressive Therapy in Patients with IgA Nephropathy revisited – clinical and histological aspects.

Jürgen Floege, Germany and Kerstin Amann, Germany

3 Repeat kidney biopsy as a biomarker in vasculitis and other GNs.

Ingeborg Bajema, Netherlands

4 Hematologic Disorders and Kidney Disease. Tiffany Caza, USA

5 Does Covid-19 or SARS-Cov-2 vaccine induce kidney disease?

Annette Bruchfeld, Sweden

6 Comorbidities in ANCA-Associated Vasculitis.

Andreas Kronbichler, United Kingdom

HALL PLENARY 8:00-8:30 (CEST)

CONGRESS OPENING

Welcome Monica Fontana (ERA Executive Director), Italy

Congress facts & figures Maria Jose Soler (Chair of Paper Selection Committee), Spain

Most important Sessions to attend Annette Bruchfeld (Chair of Scientific Committee), Sweden

Congress official opening Christoph Wanner (ERA President), Germany

59TH


MAY 19-22, 2022

8

19 T

HU


HALL S01 08:45-15:00 (CEST)

HANDS-ON COURSE ON RENAL BIOPSY

Chairs: Kate Stevens, United Kingdom Maurizio Gallieni, Italy

Trainers: Stefanie Mayer, Germany Roberta Miglio, Italy Michele Rossini, Italy Alessandra Pesino, Italy Jennifer Lees, United Kingdom

N-Path introduction Loreto Gesualdo, Italy

1 Introduction Emily McQuarrie, United Kingdom, Kai Loapu, Germany

2 Indications and epidemiology of native kidney biopsy Colin Geddes, United Kingdom

3 Practical pathology for Biopsy (Processing of the samples and tests) Candice Roufosse, United Kingdom

4 Practical pathology for Biopsy (Processing of the samples and tests) Candice Roufosse, United Kingdom

Q&A and Discussion

Procedure / Virtual simulation

1 Concluding remarks Emily McQuarrie, United Kingdom, Kai Loapu, Germany

HALL S02 08:45-12:20 (CEST)

HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA

Chairs: Josè Ibeas, Spain Tamara Jemcov, Serbia

N-Path introduction Josè Ibeas, Spain

1 Introduction Josè Ibeas, Spain Tamara Jemcov, Serbia

2 Non-maturing arteriovenous fistula Tamara Jemcov, Serbia

3 How to examine a vascular access Jernej Pajek, Slovenia


1 Virtual reality demo. From mapping to surveillance Jose Ibeas, Spain

2 Vein mapping Jernej Pajek, Slovenia

3 Stenosis Jose Ibeas, Spain

4 Thrombosis Marius Kusztal, Poland

5 Discussion

HALL S03 08:45-12:20 (CEST)

HANDS-ON COURSE ON CATHETER PLACEMENT This course will be done using Palindrome ™catheter family; please considered that similar products from other companies are available on the market

Chairs: Maria Guedes, Portugal Sokratis Stoumpos, United Kingdom

Trainers: Lucile Mercadal, France Fulvio Fiorini, Italy Kaitlin Mayne, United Kingdom Akoha Mauriac, France

N-Path introduction Maurizio Gallieni, Italy

1 Introduction Maria Guedes, Portugal Sokratis Stoumpos, United Kingdom

2 Central vein stenosis Pete Thomson, United Kingdom

3 Fibrin sheath Sokratis Stoumpos, United Kingdom

4 Kinking and tip position Maria Guedes, Portugal

5 Atrial thrombus Carlo Lomonte, Italy


HALL N04 08:45-12:20 (CEST)

CME 4 HAEMO AND PERITONEAL DIALYSIS

Chairs: Rukshana Shroff, United KingdomMehmet Kanbay, TurkeyKarlien François, Belgium

Dialysis: physiology and pathology1 Preserving residual kidney function in dialysis patients. Mehmet Kanbay, Turkey

2 Dialysis adequacy in PD and HD. Giorgina Piccoli, Italy

3 Understanding peritoneal membrane physiology - clinical implications. Johann Morelle, Switzerland

Round table discussion

Dialysis - technology1 Renal replacement therapies in natural disasters and pandemics. Carlo Basile, Italy

2 Home or institutional haemodialysis? Helena Rydell, Sweden

3 Is citrate-based dialysate the future? Karlien François, Belgium

Round table discussion

Dialysis at the extremes of age1 Pediatrics - what adult nephrologists should know about pediatric dialysis. Rukshana Shroff, United Kingdom

2 Geriatric patients - when to start dialysis and modality selection. Sandip Mitra, United Kingdom

Discussion

59TH


MAY 19-22, 2022

9

19 T

HU


HALL N01 13:00-16:40 (CEST)

CME 5 KIDNEY TRANSPLANTATION

Chairs: Marta Crespo, Spain Christophe Mariat, France Jasper Callemeyn, Belgium

1 Untangling the cause of transplant failure Klemens Budde, Germany

2 Management of chronic kidney disease after transplantation Anne-Elisabeth Heng, France

3 Immunosuppressive treatment after kidney transplant failure María José Pérez-Sáez, Spain

4 Impact of sensitization and HLA matching on repeat transplantation Aleksandar Senev, Belgium

5 Prognosis of the repeat transplantation Umberto Maggiore, Italy

HALL N02 13:00-16:40 (CEST)

CME 8 BASICS OF GENETICS FOR NEPHROLOGISTS

Chairs: Emilie Cornec Le Gal, France Roser Torra, Spain Lucille Figueres, France

1 What should I know before ordering a genetic test? Beata Lipska, Poland

2 Prescribing a genetic test: when, how, and what should be discussed with your patients before and after? Emilie Cornec Le Gal, France

3 What are the reproductive options that can be offered? Rozemarijn Snoek, Netherlands

4 How frequent are genetic diseases as cause of CKD? Roser Torra, Spain

5 Making inherited tubulopathies easy Lucille Figueres, France

6 Practical session about inherited kidney diseases Daniel Gale, United Kingdom

HALL N03 13:00-16:40 (CEST)

CME 6 ACUTE KIDNEY INJURY

Chairs: Valerie Luycks, Switzerland Vincenzo Cantaluppi, Italy Turgay Saritas, Germany

1 Novel diagnostic approaches in AKI: from urine analysis to machine learning Eric Hoste, Belgium

2 Management of AKI- fluids, catecholamine, diuretics, ultrafiltration Marlies Ostermann, United Kingdom

3 Organ system crosstalk in AKI Faeq Husain-Syed, Germany

4 Nutrition in AKI Alice Sabatino, Italy

5 Nephrotoxicity of novel cancer drugs Angel L M de Francisco, Spain

HALL N04 13:00-16:40 (CEST)

CME 7 ELECTROLYTES AND UROLITHIASIS

Chairs: Olivier Bonny, Ewout Hoorn, Jean-Philippe Bertocchio, Netherlands

1 Hyponatremia: new diagnostic and therapeutic developments. Mirjam Christ-Crain, Switzerland

2 Hypomagnesemia: from common causes to rare diseases. Tom Nijenhuis, Netherlands

3 The return of an old friend: thiazide diuretics in CKD and kidney stones. Daniel Fuster, Switzerland

4 Metabolic acidosis and citrate in CKD and kidney stones. Sandrine Lemoine, France

5 Oxalate in nephrology: emerging roles and interventions. Emmanuel Letavernier, France

59TH


MAY 19-22, 2022

10

19 T

HU


HALL S02 13:00-16:40 (CEST)

HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA

Chairs: Josè Ibeas, Spain Tamara Jemcov, Serbia

N-Path introduction Josè Ibeas, Spain

1 Introduction Josè Ibeas, Spain

2 Non-maturing arteriovenous fistula Tamara Jemcov, Serbia

3 How to examine a vascular access Jernej Pajek, Slovenia


1 Virtual reality demo. From mapping to surveillance Jose Ibeas, Spain

2 Vein mapping Jernej Pajek, Slovenia

3 Stenosis Jose Ibeas, Spain

4 Thrombosis Marius Kusztal, Poland

HALL S03 13:00-16:40 (CEST)

HANDS-ON COURSE ON CATHETER PLACEMENT This course will be done using Palindrome ™catheter family; please considered that similar products from other companies are available on the market

Chairs: Maria Guedes, Portugal Sokratis Stoumpos, United Kingdom

Trainers: Lucile Mercadal, France Fulvio Fiorini, Italy Kaitlin Mayne, United Kingdom Akoha Mauriac, France

N-Path introduction Maurizio Gallieni, Italy

1 Introduction Maria Guedes, Portugal Sokratis Stoumpos, United Kingdom

2 Central vein stenosis Pete Thomson, United Kingdom

3 Fibrin sheath Sokratis Stoumpos, United Kingdom

4 Kinking and tip position Maria Guedes, Portugal

5 Atrial thrombus Carlo Lomonte, Italy


59TH


MAY 19-22, 2022

11

19 T

HU


7 Welcome Lecture “Equity, sustainability, and ethics in kidney health” Valerie Luyckx, Switzerland

2 Presidential address Christoph Wanner, ERA President

3 Diploma and thanks Christoph Wanner to Annette Bruchfeld, Chair of the SC

4 ERA Awards

1 Welcome words Pierre Ronco, Congress President

6 Introduction to the Welcome Lecture Annette Bruchfeld, Sweden


WELCOME CEREMONY + WELCOME LECTURE

> ERA Awards for Outstanding Clinical Contribution: Ziad Massy

> Outstanding Basic Science Contributions to Nephrology: Corinne Antignac

5 Honorary Membership Andrew Levey

> Research excellence in nephrology (clinical or basic science): Andreas Linkermann

> Rosanna Gusmano Award (for young investigators in basic science): Turgay Saritas

> Stanley Shaldon Award (for young investigators in translational science): Francesco Trepiccione

> Eberhard Ritz Award (for young investigators in clinical science): Jennifer Lees

Stay updated on the latest trends in Nephrology

Exclusive for ERA Members: Hot Topics in Nephrology created by our Working Groups, EACCME® accreditation included

13

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE

CONTENT & DAILY INDEXSCIENTIFIC PROGRAMME


FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

INNOVATIONS IN PATHOLOGY TO SUPPORT NEPHROLOGISTS 16

RENAL AND CARDIAC PROTECTION IN DIABETIC AND NON-DIABETIC CKD 16

HEART AND KIDNEY: AN INSIDIOUS RELATIONSHIP 16

ERA REGISTRY 16

TRANSPLANTATION BASIC SCIENCE 17

INHERITED CYSTIC AND TUBULOINTERSTITIAL NEPHROPATHIES: NEW GENES, NEW MECHANISMS, NEW THERAPIES

17

DIAGNOSTIC TOOLS FOR AKI AND MANAGEMENT 17

PERITONEAL DIALYSIS FROM BENCH TO BEDSIDE 17

BEYOND THE BASICS OF SOCIAL MEDIA USE: ADVANCED SOCIAL MEDIA TOOLS FOR EDUCATION

18

VARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM II 18

PLENARY LECTURE 1 19

LATE BREAKING CLINICAL TRIALS 19

PHYSICAL ACTIVITIES IN CKD PATIENTS 20

CKD ARRHYTHMIAS AND ANTICOAGULATION 20

DIGNOSTICS AND THERAPEUTIC ADVANCES IN PEDIATRIC NEPHROLOGY 20

HISTOPATHOLOGY AND BEYOND IN RENAL TRANSPLANTATION 20

NOVEL TECHNIQUES - NOVEL INSIGHTS INTO KIDNEY FUNCTION 21

14

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

CLASSIFICATION OF CHRONIC KIDNEY DISEASE 21

CLINICAL ASPECTS OF TUBULAR TRANSPORT PATHOLOGY 21

NEW DIAGNOSTIC AND PROGNOSTIC TOOLS IN IGAN 21

NOVEL TOOLS FOR TRANSPLANT OUTCOME PREDICTION 22

JOINT SYMPOSIA ERA- SFNDT ARTIFICIAL INTELLIGENCE IN NEPHROLOGY 23

GENETICS PLUS X: INNOVATION FROM COMBINING TECHNOLOGIES 23

ASSESSING QUALITY OF DIALYSIS DELIVERY 23

DRUG DISCOVERY AND REPURPOSING 23

COVID, AKI AND BEYOND 24

KIDNEY GRAFT LOSS - IS IT INEVITABLE? 24

METABOLIC KIDNEY INJURY 24

RECENT ADVANCES IN THE TREATMENT OF IGAN 24

CHALLENGES IN PEDIATRIC NEPHROLOGY 25

RISK FACTORS IN CKD 25

SGLT2I IN CKD FISHBOWL SESSION 25

WHY NEPHROLOGY NEEDS ADVANCED STATISTICAL METHODS 26

PREVENTION OF CKD PROGRESSION - NEWS IN THE TRADITIONAL RISK FACTORS

26

NEW

15

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE

PLASTICITY OF RENAL CELLS 26

UPCOMING INNOVATIONS IN ACUTE KIDNEY INJURY 26

CLINICAL OUTCOMES IN TRANSPLANTATION 27

PATHOPHYSIOLOGY OF THE GLOMERULUS 27

NEW ADVANCES IN LUPUS NEPHROPATHY 27

NEW INSIGHTS FROM CLINICAL TRIALS IN ANCA-ASSOCIATED VASCULITIS 27

ASN HIGHLIGHTS 28

FRAILTY AND DIALYSIS COMPLICATIONS 28



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

59TH


MAY 19-22, 2022

16

S C I E N T I F I C P R O G R A M M E20FRI

20 F

RI

59TH


MAY 19-22, 2022


Symposium 3.1INNOVATIONS IN PATHOLOGY TO SUPPORT NEPHROLOGISTS

Chairs: Ingeborg M. Bajema, Netherlands Jan Ulrich Becker, Germany

1 Remote renal pathology counseling: Opportunites for the clinician Helen Liapis, Greece

2 Digital Data-Driven Kidney Pathology Assessment Arvydas Laurinavicius, Lithuania

3 Artificial intelligence-augmented digital nephropathology Peter Boor, Aachen, Germany

Symposium 4.1RENAL AND CARDIAC PROTECTION IN DIABETIC AND NON-DIABETIC CKD

Chairs: Maria José Soler Romeo, Spain Davide Bolignano, Italy

1 SGLT2 inhibitors: from bench to bedside for patients with cardiorenal disease Daniël van Raalte, Netherlands

2 Novel mineralocorticoid receptors antagonists: an update of mechanisms and recent trials Frederik Persson, Copenhagen

3 New kidney protective drugs: how do they impact the guidelines? Paola Fioretto, Italy

Symposium 7.1HEART AND KIDNEY: AN INSIDIOUS RELATIONSHIP

Chairs: Beatriz Fernandez Fernandez, Spain Mehmet Kanbay, Turkey

1 Lung congestion in chronic kidney failure Carmine Zoccali, Italy

2 The importance of screening and assessment of kidney function in patients with heart failure and DMT2 Martin De Borst, Netherlands

3 Uraemic Cardiomyopathy – is it truly reversible by transplantation? Charles Ferro, United Kingdom

Symposium 0.2ERA REGISTRY

Chairs: Kitty J. Jager, Netherlands Alberto Ortiz, Spain

1 Results of the European transplant survey: initiatives and barriers affecting kidney transplant rates Rianne Boenink, Netherlands

2 Mortality due to malignancies in children starting kidney replacement therapy after cancer therapy Henna Puusaari, Finland

3 Effect of dialysis initiation on health-related quality of life and symptoms in older patients Esther de Rooij, Netherlands

HALL N01 08:00-09:30 (CEST) HALL N02 08:00-09:30 (CEST) HALL N03 08:00-09:30 (CEST)

ETHICS

REGISTRY

GNC

Green Nephrology Committee

ERAC European

Renal Association Curatorium

SAB

Scienti�c Advisory Board

YNP Young Nephrologists’ Platform

ERBP European Renal Best Practice

ECC Electronic

Communication Committee

NPPCNephrology

and Public Policy Committee

ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


59TH


MAY 19-22, 2022

17


20 F

RI

59TH


MAY 19-22, 2022

Symposium 6.3TRANSPLANTATION BASIC SCIENCE

Chairs: Daniel Abramowicz, Belgium Maria C. Haller, Germany

1 Single cell technology; the role of the immune cell atlas in renal transplantation Menna Clatworthy, United Kingdom

2 Getting the most out of your data using artificial intelligence: from bench to bedside in transplantation. Or how to talk to molecular biologists? Germaine Wong, Australia

3 ABMR in the absence of anti-HLA DSAs Maarten Naesens, Belgium

HALL N04 08:00-09:30 (CEST)

Symposium 2.6INHERITED CYSTIC AND TUBULOINTERSTITIAL NEPHROPATHIES: NEW GENES, NEW MECHANISMS, NEW THERAPIES

Chairs: Marianne Verhaar, Netherlands Ron Gansevoort, Norway

1 The expanding genetic spectrum of polycystic kidney and liver diseases Emilie Cornec-Le Gall, France

2 Unravelling diseases mechanisms in ciliopathies Sophie Saunier, Paris

3 New therapeutic approaches for toxic proteinopathies, the example of ADTKD-MUC1 Moran Dvela-Levitt, Israel

Free Communication Session 34 + Mini Lectures DIAGNOSTIC TOOLS FOR AKI AND MANAGEMENT

Chairs: Christiane Erley, Germany Ben Sprangers, Belgium

ML: Nicolas Selby, United Kingdom

DEVELOPING AN AKI ALERT SYSTEM ACUTE KIDNEY INJURY AND EXPOSURE TO NEPHROTOXIC DRUGS IN CRITICALLY ILL PATIENTS: A REPORT FROM THE MULTICENTER RESCUE PROJECT IN THE NETHERLANDS Izak Yasrebi-de Kom, Netherlands

NOVEL GLUCOSE-LOWERING DRUGS AND THE RISK OF ACUTE KIDNEY INJURY IN ROUTINE CARE; THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT Jim Alkas, Sweden

STOPPING VERSUS CONTINUING RENIN-ANGIOTENSIN SYSTEM INHIBITORS AFTER ACUTE KIDNEY INJURY AND ADVERSE CLINICAL OUTCOMES; AN OBSERVATIONAL STUDY FROM ROUTINE CARE DATA Roemer Janse, Netherlands

ML: Stephane Gaudry, France ONGOING AND RECENT CLINICAL TRIALS IN AKI

Free Communication Session 24 + Mini Lectures PERITONEAL DIALYSIS FROM BENCH TO BEDSIDE

Chairs: Van Biesen, Belgium

ML: Jernej Pajek, Slovenia CHALLENGES IN TRAINING NEPHROLOGISTS FOR HOME ORIENTED CARE

MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF THE MESOTHELIAL AND ENDOTHELIAL CELL BARRIER IN HEALTH, CKD AND PERITONEAL DIALYSIS Iva Marinovic, Germany

THE ABSENCE OF STING PREVENTS PERITONEAL DAMAGE IN A MURINE MODEL OF PERITONEAL FIBROSIS Vanessa Marchant, Chile

STEVIA AS AN ALTERNATIVE OSMOTIC AGENT FOR PERITONEAL DIALYSIS FLUID Valeria Kopytina, Spain

CHANGES IN THE GUT MICROBIOME AND SYSTEMIC METABOLOME IN AN IN VIVO MODEL OF PERITONEAL DIALYSIS SUPPLEMENTED WITH ALANYL-GLUTAMINE Robin Hoogenboom, Austria

HALL S01 08:00-09:30 (CEST) HALL S02 08:00-09:30 (CEST) HALL S03 08:00-09:30 (CEST)

59TH


MAY 19-22, 2022

18


20 F

RI

59TH


MAY 19-22, 2022

Symposium 0.6BEYOND THE BASICS OF SOCIAL MEDIA USE: ADVANCED SOCIAL MEDIA TOOLS FOR EDUCATION

Chairs: Kate Stevens, United Kingdom Alexander Rosenkranz, Austria

1 Creating and distributing Visual Abstracts Menna Clatworthy, United Kingdom

2 Polarization: Morphology of Renal Networks on Twitter Tejas Desaim, USA

3 Generating data from Social Media: a tool to be taken seriously? Kate Stevens, United Kingdom

VIRTUAL HALL 1 08:00-09:30 (CEST) VIRTUAL HALL 2 08:00-09:30 (CEST)

Free Communication Session 8 + Mini LecturesVARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM II

Chairs: Maria Eriksson Svensson, Sweden Carsten Wagner, Switzerland

Sophie de Seigneux, France Renal gluconeogenesis as a novel target to reduce mortality in AKI

PHYSIOLOGICAL ROLE OF KV CHANNEL IN URETER SMOOTH MUSCLE CELL INVESTIGATED QUANTITATIVELY BY ELECTROPHYSIOLOGICAL MODELING Chitaranjan Mahapatra, India

CHRONIC HIGH PHOSPHATE LEVEL IMPAIRS CARDIAC HEALTH Andrea Grund, Germany

URIC ACID STIMULATES CYTOSKELETON PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS THROUGH F-ACTIN POLYMERIZATION AND ATROGIN, ASMA AND SM22 UP REGULATION Elisa Russo, Italy

CHARACTERIZATION OF ADIPOCYTE SIZE AND GLUCOSE UPTAKE IN ADIPOSE TISSUE WITH FOCUS ON DIFFERENT PERIRENAL FAT DEPOTS Maria Eriksson Svensson, Sweden

59TH


MAY 19-22, 2022

19


20 F

RI

59TH


MAY 19-22, 2022


PLENARY LECTURE 1

Chairs: Pierre Ronco, France Francesca Mallamaci, Italy


Symposium 0.1 LATE BREAKING CLINICAL TRIALS

Chairs: Maria Jose Soler Romeo, Spain Danilo Fliser, Germany

1 EFFECTS OF ASPIRIN IN PRIMARY PREVENTION OF CARDIOVASCULAR (CV) DISEASE IN PEOPLE WITH CHRONIC KIDNEY DISEASE (CKD): RESULTS OF THE TIPS3 TRIAL Johannes F.E. Mann, Germany

2 THE THOMAS STUDY (TOWARDS HOME-BASED ALBUMINURIA SCREENING): A RANDOMIZED STUDY INVESTIGATING TWO STRATEGIES FOR EARLY DETECTION AND TREATMENT OF CHRONIC KIDNEY DISEASE Ronald Gansevoort, Netherlands

3 IMPACT OF ALKALI THERAPY ON EGFR IN KIDNEY TRANSPLANT RECIPIENTS (PRESERVE-TRANSPLANT STUDY; NCT03102996) Nilufar Mohebbi, Switzerland

4 URINARY DKK3 PREDICTS SHORT-TERM EGFR DECLINE AND NEPHROPROTECTIVE EFFICACY OF ANTIHYPERTENSIVE THERAPY IN CHILDREN WITH CKD Franz Schaefer, Germany

5 PATIROMER FOR THE MANAGEMENT OF HYPERKALEMIA IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION RECEIVING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS: RESULTS FROM A PRESPECIFIED ANALYSIS BY EGFR FROM THE DIAMOND TRIAL Patrick Rossignol, France

6 BIO-IMPEDANCE SPECTROSCOPY (BIS) TO PRESERVE RESIDUAL KIDNEY FUNCTION (RKF) IN INCIDENT HAEMODIALYSIS (HD) PATIENTS: RESULTS OF THE BISTRO TRIAL Simon Davies, United Kingdom

PCSK9: a journey of discovery from genetics to clinical trials Catherine Boileau, France

59TH


MAY 19-22, 2022

20


20 F

RI

59TH


MAY 19-22, 2022

Symposium 7.3PHYSICAL ACTIVITIES IN CKD PATIENTS

Chairs: Jonathan Gabriel Fox, United Kingdom Sebastjan Bevc, Slovenia

1 Surveying Physical activity in CKD patients: what Nephrologists should know. Amaryllis Van Craenenbroeck, Belgium

2 Physical exercise in CKD patients: when and how is it feasible?Germaine Wong, Australia Naomi Clyne, Sweden

3 Assessment and management of obesity and metabolic syndrome in children with CKD and after kidney transplantation Stella Stabouli, Greece

HALL N01 11:45-13:15 (CEST)

Symposium 2.1DIGNOSTICS AND THERAPEUTIC ADVANCES IN PEDIATRIC NEPHROLOGY

Chairs: Emilie Cornec Le Gal, France Nine Knoers, Netherlands

1 Novel immunosuppression strategies in kidney transplantation Lars Pape, Hannover, Germany

2 Innovative therapies for nephrotic syndrome Marina Vivarelli, Italy

3 Mitochondrial diseases from childhood to adulthood Fatih Ozaltin, Turkey

Symposium 6.4HISTOPATHOLOGY AND BEYOND IN RENAL TRANSPLANTATION

Chairs: Bruno Watschinger, Austria Z. Serhan Tuglular, Turkey

1 Determinants of early graft loss: what can we learn from histopathological findings? Marlies Reinders, Netherlands

2 The importance of electron microscopy in diagnosing renal transplant rejection Candice Roufosse, United Kingdom

3 MicroRNA and Chemokine Profiles in Urine to Identify renal transplant rejection Michael Eikmans, Netherlands


Symposium 5.1CKD ARRHYTHMIAS AND ANTICOAGULATION

Chairs: Mario Cozzolino, Italy Nada Dimkovic, Serbia

1 Arrhythmias and heart failure in CKD and ESKD Karolina Szummer, Sweden

2 Anticoagulation in patients with CKD and ESKD Marie Evans, Sweden

3 Sudden death in patients with ESKD Nobuhiko Joki, Japan

59TH


MAY 19-22, 2022

21


20 F

RI

59TH


MAY 19-22, 2022

Free Communication Session 21 + Mini LecturesCLASSIFICATION OF CHRONIC KIDNEY DISEASEChairs: Catalina Martin, Spain Valerie A. Luyckx, Switzerlands

ML: Maarten Rookmaaker, Netherlands THE DIFFERENT FACES OF 'THE' RENAL FUNCTION: LOOKING BEYOND THE NORMALIZED EGFR FOR DRUG DOSING, PROGNOSTICATION AND FOLLOW UP.

CYSTATIN C TESTING IMPROVES RISK STRATIFICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE WITHOUT ADOPTING AGE-ADAPTED DIAGNOSTIC THRESHOLDS: A UK BIOBANK STUDY Jennifer Lees, United Kingdom

IMPACT OF REMOVING RACE FROM THE CKD-EPI EQUATION: ANALYSIS OF 1.6 MILLION SWEDISH ADULTS Edouard Fu, Netherlands

THE RACE-FREE EGFR EQUATION, THE KIDNEY FAILURE RISK EQUATION AND REFERRALS TO SPECIALIST RENAL CLINICS Michael Sullivan, United Kingdom

A SYSTEMS NEPHROLOGY FRAMEWORK FOR THE MOLECULAR CLASSIFICATION OF CHRONIC KIDNEY DISEASE Tobias Bohnenpoll, Germany

HALL S02 11:45-13:15 (CEST) HALL S03 11:45-13:15 (CEST)

Free Communication Session 13 + Mini LecturesNEW DIAGNOSTIC AND PROGNOSTIC TOOLS IN IGAN

Chairs: Sydney Tang, Hong Kong Sandrine Florquin, Netherlands

ML: Fernando Caravaca-Fontán, Spain TREATMENT DURATION AND EFFICACY IN C3 GLOMERULOPATHY

POPULATION-BASED IDENTIFICATION OF BIOPSY PROVEN IGA NEPHROPATHY USING NATURAL LANGUAGE PROCESSING: THE KNIGHT STUDY Alan Go, USA

AUTOMATED MEST-C CLASSIFICATION IN IGA NEPHROPATHY USING DEEP-LEARNING BASED SEGMENTATION Elise Marechal, France

RNA SEQUENCING OF MICRODISSECTED KIDNEY BIOPSIES FROM IGA NEPHROPATHY PATIENTS Anna Levin, Sweden

NEW TOOL TO PREDICT THE CLINICAL COURSE AND RENAL FAILURE IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY. Francesco Paolo Schena, Italy

VIRTUAL HALL 1 11:45-13:15 (CEST)

Symposium 1.1NOVEL TECHNIQUES - NOVEL INSIGHTS INTO KIDNEY FUNCTION

Chairs: Giovambattista Capasso, Italy Stephen Walsh, United Kingdom

1 Urinary extracellular vesicles and tubular transport Ewout J Hoorn, Netherlands

2 Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay. Tomoko Horinouchi, Japan

3 2-Photon microscopy and Cell-fate tracking reveals novel repair mechanisms in kidney injury Ina Schiessl, Denmark

HALL S01 11:45-13:15 (CEST)

Free Communication Session 4 + Mini LecturesCLINICAL ASPECTS OF TUBULAR TRANSPORT PATHOLOGY

Chairs: Giovanni Gambaro, Italy Inagi Reiko, Japan

ML: Michael Straub, Germany MEDULLARY SPONGE KIDNEY AND RTA - A CHALLENGE AT THE NEPHROLOGY AND UROLOGY JUNCTION

MULTICENTRIC EXPERIENCE WITH RNA INTERFERENCE MEDICATION (OXLUMO®) IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 Bernd Hoppe, Germany

EFFECT OF URINE ALKALINAZATION ON URINARY INFLAMMATORY MARKERS ANALYZED BY MASS SPECTROMETRY IN PATIENTS WITH CYSTINURIA Caroline Prot-Bertoye, France

URINARY LITHOGENIC PROFILE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE Matteo Bargagli, Italy

SHEAR WAVE ELASTOGRAPHY EFFECTIVE IN ULTRASOUND DIAGNOSIS OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH HYPERURICEMIA AND GOUT Rostyslav, Ukraine

59TH


MAY 19-22, 2022

22


20 F

RI

59TH


MAY 19-22, 2022

Free Communication Session 28 + Mini LecturesNOVEL TOOLS FOR TRANSPLANT OUTCOME PREDICTION

Chairs: My Svensson, Norway Alexander Rosenkranz, Austria

ML: Annemarie Weissenbacher, Austria TAILORING IMMUNOSUPPRESSION: LESSONS FROM THE IMMUNOLOGY LAB.

MULTIDIMENSIONAL PROGNOSTICATION TOOL FOR KIDNEY TRANSPLANT PATIENT SURVIVAL: THE MORTALITY MBOX. Charlotte Debiais-Deschamps, France

OF THE OPTIMAL TORQUE TENO VIRUS RANGE FOR RISK STRATIFICATION OF GRAFT REJECTION AND INFECTION IN KIDNEY TRANSPLANT RECIPIENTS BY TTV R-GENE® Frederik Haupenthal, Austria

DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING BASED VIRTUAL BIOPSY SYSTEM IN KIDNEY TRANSPLANT PATIENTS Daniel Yoo, France

ML: My Svensson, Norway WHAT HAPPENED TO BELATACEPT


59TH


MAY 19-22, 2022

23


20 F

RI


Symposium 0.7JOINT SYMPOSIA ERA- SFNDT ARTIFICIAL INTELLIGENCE IN NEPHROLOGY

Chairs: Maryvonne Hourmant, France Jadranka Buturovi -Ponikvar, Slovenia

1 From the database to the clinic Alexandre Loupy, France

2 From the database to the clinic Pierre-Antoine Gourraud, France

3 Artificial intelligence in nephropathology Vincent Vuiblet, France

4 Connected stools in nephrology Patrick Jourdain, France

59TH


MAY 19-22, 2022

Symposium 3.2GENETICS PLUS X: INNOVATION FROM COMBINING TECHNOLOGIES

Chairs: Albertien van Eerde, Netherlands John Sayer, United Kingdom

1 Combining exome sequencing with reverse phenotyping in steroid-resistant nephrotic syndrome Francesca Becherucci, Italy

2 Engineering human tissues for studying kidney disease, drug testing and replacement therapies. Christodoulos Xinaris, Cyprus

3 Combining exome sequencing with urinary metabolomics to unravel inborn errors of metabolism. Anna Köttgen, Germany

Symposium 5.2ASSESSING QUALITY OF DIALYSIS DELIVERY

Chairs: Edwina Brown, United Kingdom Carlo Basile, Italy

1 Are we aware of the extent to which the quality of dialysis depends on vascular access? Jose Ibeas, Spain

2 Goal directed dialysis: individualising the prescription - can HD learn from PD? Albert Power, United Kingdom

3 Generic or individualised patient outcome measures? Esmee M. van der Willik, Netherlands

Symposium 4.4 DRUG DISCOVERY AND REPURPOSING

Chairs: Ziad Massy, France Lisbet Brandi, Denmark

1 Drug repurposing: From kidney diseases to COVID-19 Anna Greka, USA

2 RNA therapeutics for rare diseases: hyperoxaluria and beyond Justine Bacchetta, France

3 Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD Cristina Podrini, Italy


59TH


MAY 19-22, 2022

24


20 F

RI

Symposium 8.4COVID, AKI AND BEYOND

Chairs: Nicholas Selby, United Kingdom Maria Prendecki, United Kingdom

1 AKI during COVID-19 infection: specific or non-specific renal injury? Tobias Huber, Germany

2 Brain changes in nephroCovid19 patients Davide Viggiano, Italy

3 Long-Covid and clincial implications Judith Bruchfeld, Sweden

59TH


MAY 19-22, 2022

Free Communication Session 29 + Mini LecturesKIDNEY GRAFT LOSS - IS IT INEVITABLE?

Chairs: Lizia Peruzzi, Italy Dimitrios Goumenos, Greece

ML: Alica Debska Slizien, Poland WHEN OBESITY IS A PROBLEM IN KIDNEY TRANSPLANT CANDIDATES AND RECIPIENTS?

GENE EXPRESSION PROFILES OF PERITUBULAR CAPILLARITIS IN CHRONIC ANTIBODY-MEDIATED REJECTION Michael Eder, Austria

MICROVASCULAR INFLAMMATION IN KIDNEY TRANSPLANT BIOPSIES IN THE ABSENCE OF HLA-DSA DISPLAYS INTENSE CYTOTOXIC T-CELL AND NK CELL BUT NOT PLASMA CELL INFILTRATION Anna Buxeda, Spain

SURVIVAL BENEFIT OF PREEMPTIVE SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION Enrique Montagud-Marrahi, Spain

A COMORBIDITY INDEX AND PRETRANSPLANT PHYSICAL STATUS PREDICT SURVIVAL IN OLDER KIDNEY TRANSPLANT RECIPIENTS Vasiliki Tsarpali, Norway

Free Communication Session 14 + Mini LecturesRECENT ADVANCES IN THE TREATMENT OF IGAN

Chairs: Rosanna Coppo, Italy Michel Jadoul, Belgium

ML: Rosanna Coppo, Italy COMPLEMENT INHIBITION IN IGA NEPHROPATHY

NEFECON® (BUDESONIDE) IS AN EPIGENETIC MODIFIER IN IGA NEPHROPATHY Jasraj Bhachu, United Kingdom

NEFECON® SELECTIVELY MODIFIES THE COMPOSITION OF CIRCULATING IMMUNE COMPLEXES IN IGA NEPHROPATHY Karen Molyneux, United Kingdom

ATACICEPT REDUCES SERUM ANTI-GD-IGA1 LEVELS IN IGAN PATIENTS Jonathan Barratt, United Kingdom

ATRASENTAN FOR THE TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS FROM THE AFFINITY STUDY Muh Wong, Australia

HALL S01 15:00-16:30 (CEST)HALL N04 15:00-16:30 (CEST) HALL S02 15:00-16:30 (CEST) HALL S03 15:00-16:30 (CEST)

Free Communication Session 32 + Mini LecturesMETABOLIC KIDNEY INJURY

Chairs: Laetitia Koppe, France Marcin Adamczak, Poland

ML: Jung Tak Park, South Korea BODY COMPOSITION AND KIDNEY FUNCTION

KIDNEY-SPECIFIC SILENCING OF NEAT1 ALLEVIATES DIABETIC KIDNEY INJURY Rui Xue Hong Kong, P.R. China

LIPID CHANGES AS EARLY INDICATOR FOR DIABETES INDUCED RENAL PATHOLOGY Rosalie Rietjens, Netherlands

THE COMBINATION OF EMPAGLIFLOZIN AND ATRASENTAN ON TOP OF RAS BLOCKADE AMELIORATES CARDIORENAL INJURY IN A TYPE 2 DIABETIC MOUSE MODEL Ander Vergara Arana, Spain

ML: Mingyu Liang, USA RENAL METABOLISM AND HYPERTENSION

59TH


MAY 19-22, 2022

25


20 F

RI

Free Communication Session 1 + Mini LecturesRISK FACTORS IN CKD

Chairs: Orsolya Cseprekal, Hungary Peter Stenvinkel, Sweden

ML: Lucia Del Vecchio, Italy OBESITY AS A HEALTH ISSUE: HOW COVID 19 PANDEMICS AMPLIFIED IT AS A SCARING RISK FACTOR.

HUMORAL RESPONSE TO THIRD DOSE OF SARS-COV-2 VACCINES IN THE CKD SPECTRUM: THE SENCOVAC STUDY Borja Quiroga, Spain

HUMORAL AND CELLULAR IMMUNE RESPONSES AFTER A THREE-DOSE COURSE OF MRNA-1273 COVID-19 VACCINE IN KIDNEY TRANSPLANT RECIPIENTS: A PROSPECTIVE COHORT STUDY David Cucchiari, Spain

ASSOCIATION BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE AND HYPERFILTRATION IN SUBJECTS WITH PREDIABETES AND ABDOMINAL OBESITY WITHOUT EVIDENCE OF CHRONIC KIDNEY DISEASE Aneliya Parvanova, Italy

ML: Peter Stenvinkel, Sweden FOOD AS MEDICINE – CAN IT LINK THE GUT MICROBIOTA TO AN IMPROVED RENAL PHENOTYPE?

SGLT2I IN CKD FISHBOWL SESSION

59TH


MAY 19-22, 2022

VIRTUAL HALL 1 15:00-16:30 (CEST) VIRTUAL HALL 2 15:00-16:30 (CEST) MINI ORAL HALL 16:30-17:00 (CEST)

Symposium 2.2CHALLENGES IN PEDIATRIC NEPHROLOGY

Chairs: Peter Barany, Sweden Elena Levtchenko, Belgium

1 Rewired: neurocognitive function in CKD Jaap Groothoff, Netherlands

2 Transition adolescent with CKD to adult clinics Gema Ariceta, Spain

3 Isotope diagnostics to improve CKD-MBD management Rukshana Shroff, United Kingdom

NEW

Chair: Mario Cozzolino, Italy

Patrick Mark, United Kingdom

Ionut Nistor, Romania

Beatriz Fernandez Fernandez, Spain

Panellists:

59TH


MAY 19-22, 2022

26


20 F

RI

59TH


MAY 19-22, 2022

Symposium 0.2.1WHY NEPHROLOGY NEEDS ADVANCED STATISTICAL METHODS

Chairs: Ivan Rychlik, Czech Republic Vivek Jha, India

1 Target Trial Emulation: Implications for outcome studies on timing of dialysis initiation Edouard Fu, Netherlands

2 Target Trial Emulation: Implications for transplant survival studies Vianda Stel, Netherlands

3 Joint Models – Applications in nephrology Nick Chesnaye, Netherlands

Symposium 4.8 PREVENTION OF CKD PROGRESSION - NEWS IN THE TRADITIONAL RISK FACTORS

Chairs: Tilman B. Drüeke, France Marie Evans, Sweden

1 Diabetic kidney disease - early detection and subsequent intervention for delaying the progression Goce Spasovski, Republic of North Macedonia

2 Acute Kidney Injury in Patients with Chronic Kidney Disease: is an adequate prevention possible? Mustafa Arici, Turkey

3 Prevention of CKD progression - news in the traditional risk factors Francesca Mallamaci, Italy

Symposium 1.2PLASTICITY OF RENAL CELLS

Chairs: Sola Aoun Bahous, Lebanon Robert Fenton, Denmark

1 The plasticity of renin-producing cells Armin Kurtz, Germany

2 The different facets of Myofibroblasts in kidney Rafael Kramann, Germany

3 Proximal tubule dysfunction in Glycogen Storage Disease Francesco Trepiccione, Italy

Symposium 8.1 UPCOMING INNOVATIONS IN ACUTE KIDNEY INJURY

Chairs: Thimoteus Speer, Germany Christiane Erley, Germany

1 Deciphering the molecular mechanisms of necroinflammation in acute tubular necrosis Wulf Tonnus, Germany

2 What is to come in the next KDIGO AKI guideline? Marlies Ostermann, United Kingdom

3 Identifying patients at risk of the AKI-to-CKD transition Morgan Grams, USA

HALL PLENARY 17:00-18:30 (CEST) HALL N01 17:00-18:30 (CEST) HALL N02 17:00-18:30 (CEST) HALL N03 17:00-18:30 (CEST)

ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


59TH


MAY 19-22, 2022

27


20 F

RI

59TH


MAY 19-22, 2022

Free Communication Session 30 + Mini LecturesCLINICAL OUTCOMES IN TRANSPLANTATION

Chairs: Ewa Pawlowicz, Poland Peter Barany, Sweden

ML: Miroslaw Wielgos, Poland FERTILITY PROBLEMS IN KIDNEY TRANSPLANT RECIPIENTS MALE OB/GYN

HLA-SPECIFIC MEMORY B CELLS AND PATERNAL HLA MOLECULAR MISMATCH IN FEMALE TRANSPLANT CANDIDATES SENSITIZED BY PREGNANCY Sara Sanz-Ureña, Spain

DEVELOPMENT AND VALIDATION OF AN INTEGRATIVE DD-CFDNA SYSTEM TO PREDICT ALLOGRAFT REJECTION: A POPULATION BASED STUDY Olivier Aubert, France

MONOCLONAL GAMMOPATHY IN KIDNEY TRANSPLANTED PATIENTS: NOVEL INSIGHTS INTO LONG-TERM OUTCOMES Marie-Sophie Meuleman, France

LONG-TERM OUTCOMES IN ECULIZUMAB-TREATED KIDNEY TRANSPLANT PATIENTS ENROLLED IN THE GLOBAL ATYPICAL HAEMOLYTIC URAEMIC SYNDROME REGISTRY Maria Gema Ariceta Iraola, Spain

Free Communication Session 5 + Mini LecturesPATHOPHYSIOLOGY OF THE GLOMERULUS

Chairs: Tobias Huber, Germany Paola Romagnani, Italy

ML: Anna Lervolino, Italy ZEBRAFISH LARVAE TO STUDY AND TREAT GLOMERULAR DISEASES

TARGET DECONVOLUTION FROM PHENOTYPIC SCREENS – IDENTIFICATION OF ATAXIA TELANGIECTASIA MUTATED AS A POTENTIAL THERAPEUTIC TARGET FOR PODOCYTE PROTECTION Jürgen Stumm, Germany

HIGH SALT ENVIRONMENT DISRUPTS THE REGULATORY EFFECT OF PODOCIN ON THE NEPHRIN-NEPHRIN DISTANCE Violetta Antal-Kónya, Hungary

NEPHROTOXICITY OF ANTIANGIOGENIC THERAPIES: DIRECT IMPACT OF SORAFENIB ON THE PODOCYTE VIA GSK3B Margaux Van Wynsberghe, France

ADAPTIVE REMODELING OF MESANGIAL EXTRACELLULAR MATRIX PROTEOGLYCAN COMPOSITION DURING IGA NEPHROPATHY Alva Johansson, Sweden

Free Communication Session 15 + Mini LecturesNEW ADVANCES IN LUPUS NEPHROPATHY

Chairs: Iva Gunnarsson, Sweden Liz Lightstone, United Kingdom

ML: Hans-Joachim Anders, Germany A FAREWELL TO THE CONCEPT OF INDUCTION AND MAINTENANCE THERAPY IN LUPUS NEPHRITIS

WEANING OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY IN LUPUS NEPHRITIS (WIN-LUPUS): A MULTICENTER RANDOMIZED CONTROLLED TRIAL. Noemie Jourde-Chiche, France

VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY Y.K.O. Teng, Netherlands

EFFECT OF ATACICEPT ON RENAL FUNCTION IN SLE PATIENTS David Isenberg, United Kingdom

EARLY REDUCTIONS IN PROTEINURIA WITH VOCLOSPORIN TREATMENT ACROSS LUPUS NEPHRITIS BIOPSY CLASSES: POOLED DATA FROM THE AURA-LV AND AURORA 1 TRIALS Anca Askanase, United States Minor Outlying Islands

Free Communication Session 16 + Mini LecturesNEW INSIGHTS FROM CLINICAL TRIALS IN ANCA-ASSOCIATED VASCULITIS

Chairs: Elena Zakarova, Russia, Annette Bruchfeld, Sweden

ML: Elena Csernok, Germany ASSAYS FOR ANTI-GBM ANTIBODIES AND DETECTION PROBLEMS

INCIDENCE OF INFECTIONS IN THE AVACOPAN GROUP VERSUS PREDNISONE GROUP IN ANCA-ASSOCIATED VASCULITIS, RESULTS FROM THE PHASE 3 ADVOCATE STUDY Michael George, USA

LONG-TERM RENAL SURVIVAL OF ANCA-ASSOCIATED VASCULITIS PATIENTS INCLUDED IN THE EUVAS RANDOMIZED CLINICAL TRIALS Beatriz Sanchez Alamo, Spain

CARDIOVASCULAR OUTCOMES IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS IN DENMARK 1996-2018 Louis Nygaard Pedersen, Denmark

MALIGNANCIES IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITHIN THE EUVAS TRIALS Beatriz Sanchez Alamo, Spain

HALL S01 17:00-18:30 (CEST)HALL N04 17:00-18:30 (CEST) HALL S02 17:00-18:30 (CEST) HALL S03 17:00-18:30 (CEST)

59TH


MAY 19-22, 2022

28


20 F

RI

59TH


MAY 19-22, 2022

Symposium 0.3ASN HIGHLIGHTS

Chairs: Karin True, USA Patrick H. Nachman, USA

1 AKI Anitha Vijayanm, USA

2 General Nephrology and CKD Delphine S. Tuot, USA

3 Hypertension Tara I. Chang, USA

Free Communication Session 25 + Mini LecturesFRAILTY AND DIALYSIS COMPLICATIONS

Chairs: Blankestijn, Peter J., Netherlands Ekart Robert, Slovenia

ML: Andrew Nixon, United Kingdom EMBEDDING NEEDS OF OLDER PEOPLE INTO ROUTINE MANAGEMENT OF ESKD

THE RELATIONSHIP BETWEEN CEREBROVASCULAR REACTIVITY AND INTRADIALYTIC CEREBRAL PERFUSION Dawn Wolfgram, USA

SYMPTOM BURDEN AND INDIVIDUAL SYMPTOMS BEFORE AND AFTER DIALYSIS INITIATION IN OLDER PATIENTS Esther De Rooij, Netherlands

FRAX IS USEFUL TOOL FOR PREDICTING ALL-CAUSE MORTALITY IN ADDITION TO THE RISK OF FRAGILE FRACTURE IN HEMODIALYSIS PATIENTS Takayuki, Fujii Japan

DEVELOPMENT AND VALIDATION OF AN AI-BASED TRIAGE ALGORITHM FOR INTENSIFIED PREVENTION OF INTRADIALYTIC HYPOTENSION. Federica Gervasoni, Italy


www.era-online.org

Join the ERA Community

Discover the Membership benefits at the ERA booth

30

21SAT

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

INNOVATIVE TECHNOLOGIES PROVIDING INNOVATIVE INSIGHTS: KIDNEY REMODELLING UPON INJURY

33

EXPANSION OF HOME THERAPIES IN EUROPE: DESIRABLE AND POSSIBLE? 33

2021 PEARLS OF NDT AND CKJ 33

PHOSPHATE IN CKD FROM BENCH TO BEDSISDE 33

BRIDGING THE GAP BETWEEN GENETICS AND NEPHROLOGY WORLDS: LET'S ALL BECOME NEPHROGENETICISTS

34

PHYSIOLOGY OF PODOCYTES: CLINICAL IMPLICATIONS 34

AKI MECHANISMS FROM PROMOTERS TO INHIBITORS 34

CLINICAL OUTCOMES IN DIABETIC KIDNEY DISEASE AND CV COMPLICATIONS

34

CKD IN EUROPE, THE VOICE OF THE PATIENTS 35

ERA GENERAL ASSEMBLY 35

SCREENING FOR EARLY CKD - THE IMPORTANCE FOR CARDIOVASCULAR RISK MANAGEMENT

35

BIOELECTRONIC MEDICINE, HYPERTENSION AND INFLAMMATION 36

CACHEXIA OR PROTEIN ENERGY WASTING: WHAT IS NEW IN CKD? 36

THE CONNECT PROJECT: COGNITIVE DECLINE IN NEPHRO-NEUROLOGY: EUROPEAN COOPERATIVE TARGET

37

ONCONEPHROLOGY 37

ANCA-ASSOCIATED KIDNEY VASCULITIS ACROSS LIFETIME 37

31

21SAT

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

PERSONALISED MEDICINE 37

CV COMPLICATIONS IN DIALYSIS 38

PATIENT-REPORTED OUTCOME MEASURES - DOES IT IMPROVE HEALTH-CARE?

38

PREDICTORS OF OUTCOME IN ANCA-ASSOCIATED VASCULITIS 38

NEW TRENDS IN CKD 38

TREATMENT FOR CKD 39

A FAREWELL TO HYPERTENSIVE NEPHROSCLEROSIS 40

CHOICE OF KRT 40

NEW AVENUES IN LUPUS NEPHRITIS 40

IS MICROBIOTA RESPONSIBLE FOR THE UREMIC TOXICITY? 40

TUBULAR TRANSPORT 41

CLINICAL ASPECTS OF AKI PREVENTION AND TREATMENT 41

GENETIC SCREENING FOR CHRONIC KIDNEY DISEASE 41

RENOPROTECTIVE DRUGS IN KIDNEY TRANSPLANTATION - READY FOR PRIME TIME?

41

NEPHROTIC SYNDROME FROM CHILDHOOD TO ADULTHOOD 42

COVID-19 AND OXYGEN 42

32

21SAT

59TH


MAY 19-22, 2022

DAY AT A GLANCE

CKD-MBD IN ESKD – TRADITIONAL AND NOVEL APPROACHES 43

IMMUNOCOMPETENCE IN RENAL TRANSPLANTATION 43

BRIDGING THE GAPS BETWEEN BASIC SCIENCE AND HUMAN TRIALS FOR KIDNEY HEALTH INTERVENTIONS

43

HOW TO OPTIMALLY PREVENT PROGRESSION IN ADPKD 43

AKI-CKD TRANSITION - IS IT INEVITABLE? 44

HUMAN URINE AS THE WINDOW OF RENAL DISEASE 44

VARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM I 44

GENE AND CELL THERAPY COME OF AGE FOR THE NEPHROLOGIST 44

SEX DIFFERENCES IN NEPHROLOGY - DOES IT MATTER FOR PATIENT OUTCOME?

45

PEDIATRIC NEPHROLOGY 45



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

59TH


MAY 19-22, 2022

33

S C I E N T I F I C P R O G R A M M E21SAT

21 S

AT

59TH


MAY 19-22, 2022

Symposium 3.4INNOVATIVE TECHNOLOGIES PROVIDING INNOVATIVE INSIGHTS: KIDNEY REMODELLING UPON INJURY

Chairs: Martin De Borst, Netherlands Beatriz Sanchez Alamo, Spain

1 Single cell RNA sequencing of the human kidney: Identifying new drug targets for kidney fibrosis. Christian Kuppe, Germany

2 Clonal lineage tracing: The glomerular crescent in RPGN is a monoclonal lesion that responds to clone-directed therapy Paola Romagnani, Italy

3 Tissue proteomics to monitor stress responses in the kidney Markus Rinschen, Denmark

Symposium 5.3EXPANSION OF HOME THERAPIES IN EUROPE: DESIRABLE AND POSSIBLE?

Chairs: Nicola Matthews, Canada Tamara Jemcov, Serbia

1 Why does use of home therapies vary across Europe? Maria Slon Roblero, Spain

2 Variability of home therapies use in UK units: early results from the Inter-CEPt study Simon Davies, United Kingdom

3 Does access to assisted PD increase use of PD Anita van Eck van der Sluijs, Netherlands

Symposium 0.42021 PEARLS OF NDT AND CKJ

Chairs: Denis Fouque, France Maria José Soler, Spain

1 NDT Marlies Ostermann, United Kingdom Hans-Joachim Anders, Germany

2 CKJ Roser Torra, Spain Will Herrington, United Kingdom

Symposium 4.6 PHOSPHATE IN CKD FROM BENCH TO BEDSISDE

Chairs: Amaryllis Van Craenenbroeck, Belgium Juan Jesus Carrero, Sweden

1 Consequences of phosphate meeting cholesterol Xiong Z. Ruan, United Kingdom

2 Targeting NaPi-IIb for hyperphosphatemia in CKD Patients - The Dead End? Mugurel Apetrii, Romania

3 Intestinal phosphate binders to reduce cardiovascular risk in patients with CKD? Nigel Toussaint, Australia

HALL N02 08:00-09:30 (CEST)HALL N01 08:00-09:30 (CEST) HALL N03 08:00-09:30 (CEST) HALL N04 08:00-09:30 (CEST)

59TH


MAY 19-22, 2022

34


21 S

AT

59TH


MAY 19-22, 2022

Symposium 2.4BRIDGING THE GAP BETWEEN GENETICS AND NEPHROLOGY WORLDS: LET'S ALL BECOME NEPHROGENETICISTS

Chairs: Rukshana Shroff, United Kingdom Franz Schaefer, Germany

1 How the genomics England consortium changed nephrogenetics in England. Daniel Gale, United Kingdom

2 Genetic-first approaches in ESKD of unknown significance Laurent Mesnard, France

3 What about the kids: practical aspects of care for children at risk of genetic disease that all adult nephrologists should know. Mekahli Djalila, Belgium

Symposium 1.4PHYSIOLOGY OF PODOCYTES: CLINICAL IMPLICATIONS

Chairs: Rachel Lennon, United Kingdom Marc Vervloet, Netherlands

1 Super-resolution microscopy meets kidney research and diagnosis Nicole Endlich, Germany

2 Vitamin D3 influences the differentiation of podocytes in situ and in vitro Tim Lange, Germany

3 Podocyte lipid metabolism Catherine Meyer-Schwesinger, Germany

HALL S02 08:00-09:30 (CEST)HALL S01 08:00-09:30 (CEST)

Free Communication Session 35 + Mini LecturesAKI MECHANISMS FROM PROMOTERS TO INHIBITORS

Chairs: Clara García-Carro, Spain Andrzej Jan Wiecek, Poland

ML: Mehmet Kanbay, Turkey SGLT2 INHIBITORS AND AKI

KINETICS OF RENAL INJURY AFTER RHABDOMYOLYSIS: IMPLICATION OF INNATE IMMUNE CELLS AND COMPLEMENT ACTIVATION Anne Grunenwald, France

KIDNEY INJURY MOLECULE-1-MEDIATED SMALL EXTRACELLULAR VESICLES UPTAKE IS CRUCIAL FOR RENAL TUBULOINTERSTITIAL INFLAMMATION Jun Chen, P.R. China

DEFICIENCY OF PROXIMAL TUBULAR CYCLIN-DEPENDENT KINASE 12 EXACERBATES KIDNEY INJURY THROUGH DNA-DAMAGE RESPONSE Yilin zhang, P.R. China

HALL S03 08:00-09:30 (CEST)

Free Communication Session 33 + Mini LecturesCLINICAL OUTCOMES IN DIABETIC KIDNEY DISEASE AND CV COMPLICATIONS

Chairs: Lucia Del Vecchio, Italy Peter Rossing, Denmark

OF CANAGLIFLOZIN ON CARDIOVASCULAR AND KIDNEY EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT PERIPHERAL VASCULAR DISEASE: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL Adeera Levin, Canada

BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE Vlado Perkovic, Australia

REAL-WORLD USE OF ONCE-WEEKLY SEMAGLUTIDE BY BASELINE ESTIMATED GLOMERULAR FILTRATION RATE – A POST HOC ANALYSIS OF POOLED DATA FROM THE SURE STUDIES (CANADA, DENMARK/SWEDEN, SWITZERLAND AND UNITED KINGDOM) Gottfried Rudofsky, United Kingdom

COMPARATIVE EFFECTIVENESS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS VERSUS SULFONYLUREAS IN ADDITION TO METFORMIN: A POPULATION-BASED COHORT STUDY OF PATIENTS WITH DIABETES Hon-Yen Wu Taiwan, R.O.C.

ASSOCIATION BETWEEN CIRCULATING LEVELS OF 25-HYDROXYVITAMIN D AND METALLOPROTEINASE-10 (MMP 10) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. CROSS SECTIONAL STUDY. Abasheva Daria, Spain


59TH


MAY 19-22, 2022

35


21 S

AT

59TH


MAY 19-22, 2022

ERA GENERAL ASSEMBLY All ERA active members are invited to participate in the ERA General Assembly.

Members (and their status of FULL or ASSOCIATE) will be automatically recognized by the system. Full members will be able to vote (Associate members - cannot vote but they can ask questions).

Part I 09.30 - 09.40

OPENING Welcome, Christoph Wanner (President)

1 Minutes of the 58th General Assembly, Ivan Rychlik (Secretary-Treasurer)

Part II 09.40 - 10.30

2 Report from the President, Christoph Wanner

3 Report from the Secretary‐Treasurer, Ivan Rychlik

4 Report from the Renal Science Chair, Danilo Fliser

5 Report from the Clinical Nephrology Governance Chair, Alberto Ortiz

Part III 10.30 - 10.45

6 Election of the Ordinary Council Member (one vacancy), Christoph Wanner

7 Venue and date of the 2024 ERA Congress, Christoph Wanner

8 Date and venue of the next General Assembly, Ivan Rychlik

9 Any other business FERA awards, Ivan Rychlik

CLOSURE, Christoph Wanner


Symposium 0.8CKD IN EUROPE, THE VOICE OF THE PATIENTS

Chairs: Jan van Cruchten, Netherlands Lucile Mercadal, France

CKD in Europe: 100 million people with kidney disease Raymond Vanholder, Belgium

The experience of patients in France during the pandemic Christian Baudelot, France

The role of patients and their associations in crisis management Yvanie Caillé, France

The role of patients and their associations in crisis management Anne Stinat, France


VOTE!

SCREENING FOR EARLY CKD - THE IMPORTANCE FOR CARDIOVASCULAR RISK MANAGEMENTChairs: Alexander Rosenkranz, Austria Ronald Gansevoort, Netherlands

1 The importance of Real Word Evidence in Early Screening and Detection of CKD Navdeep Tangri, Canada

2 The place of CKD in guidelines for Cardiovascular Risk Management Nikolaus Marx, Germany

3 One step beyond: towards population screening for CKD? Lyanne Kieneker, Netherlands

4 Raising awareness among physicians and the public Katharina Andrea Schütt, Germany

This symposium is organized by the European Renal Association Curatorium (ERAC) honoring the recent start of several CKD screening and awareness programs across Europe: Strong Kidneys, Guardians for Health, REVEAL CKD, INSIDE CKD, the Kidney Health Action Group, and the THOMAS study

ERA MEETING ROOM 1 13:30-14:30 (CEST)

ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


59TH


MAY 19-22, 2022

36


21 S

AT

59TH


MAY 19-22, 2022

Plenary Lecture 2BIOELECTRONIC MEDICINE, HYPERTENSION AND INFLAMMATION

Chairs: Giovambattista Capasso, Italy Annette Bruchfeld, Sweden

Symposium 4.2 CACHEXIA OR PROTEIN ENERGY WASTING: WHAT IS NEW IN CKD?

Chairs: Denis Fouque, France Carla Avesani, Sweden

1 Time to abandon the restriction of fruits and vegetables in patients with chronic kidney disease? Juan Jesus Carrero, Sweden

2 The role of browning in CKD cachexia Laetitia Koppe, France

3 Intramuscle fat infiltration in CKD: a marker related to muscle quality, muscle strength and sarcopenia Carla Avesani, Sweden

HALL N01 10:45-11:30 (CEST) HALL PLENARY 11:45 - 13:15 (CEST)

Bioelectronic Medicine, hypertension and inflammation Kevin Tracey, USA

59TH


MAY 19-22, 2022

37


21 S

AT

59TH


MAY 19-22, 2022

Symposium 6.1ONCONEPHROLOGY

Chairs: Smaragdi Marinaki, Greece Rainer Oberbauer, Austria

1 Immune Checkpoint Inhibitor Therapy in solid organ recipients Maria Soler, Spain

2 Haematological malignancies post transplant – what’s new? Ben Sprangers, Belgium

3 Can Nephrologist improve the Outcomes of Cancer patients? Mariadelina Simeoni, Italy

Symposium 3.5 ANCA-ASSOCIATED KIDNEY VASCULITIS ACROSS LIFETIME

Chairs: Andreas Kronbichler, United Kingdom Kerstin Westman, Sweden

1 Pathophysiology of ANCA-associated vasculitis: an update David Jayne, United Kingdom

2 ANCA-associated kidney vasculitis in childhood Augusto Vaglio, Italy

3 ANCA-associated Kidney vasculitis in adults and in the eldely Maria Weiner, Sweden

Free Communication Session 9 + Mini LecturesPERSONALISED MEDICINE

Chairs: Ron Gansevoort, Netherlands

ML: Francesca Becherucci, Italy PERSONALISED DIAGNOSIS AND CKD PREDICTION IN GENETIC TUBULAR DISORDERS

A MULTIVARIATE MODEL IDENTIFIES GENOTYPE, HYPERTENSION AND KIDNEY LENGTH AS INDEPENDENT BASELINE PREDICTORS OF DISEASE PROGRESSION IN A LONGITUDINAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENT COHORT Wen Cong Eugene, United Kingdom

DIAGNOSTIC YIELD OF EXOME SEQUENCING IN HYPERTENSIVE NEPHROPATHY Justine Serre, France

VALIDATION OF A PREDICTION SYSTEM FOR RISK OF ALLOGRAFT LOSS (IBOX) IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS Julien Hogan, France

COPEPTIN AS A POTENTIAL BIOMARKER IN PATIENTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) - UPDATE FROM THE AD(H)PKD STUDY Simon Oehm, Germany

Symposium 5.7THE CONNECT PROJECT: COGNITIVE DECLINE IN NEPHRO-NEUROLOGY: EUROPEAN COOPERATIVE TARGET

Chairs: Elena Zakharova, Russia Sanjin Racki, Croatia

1 How the kidney may affect brain cognitive function Giovambattista Capasso, Italy

2 Evidence on albuminuria as a risk factor for dementia Gaye Hafez, Turkey

3 Cognitive function in dialytic and transplanted patients Casper Franssen, Netherlands

HALL N01 11:45-13:15 (CEST) HALL S04 11:45-13:15 (CEST)HALL N03 11:45-13:15 (CEST)HALL N02 11:45-13:15 (CEST)

59TH


MAY 19-22, 2022

38


21 S

AT

59TH


MAY 19-22, 2022

Symposium 7.2CV COMPLICATIONS IN DIALYSIS

Chairs: My Svensson, Norway Inga Arune Bumblyte, Lithuania

1 ABPM in CKD 5D: does surge BP matter for outcomes? Olga Balafa, Greece

2 ABPM use in CKD patients: opportunities and challenges Pantelis Sarafidis, Greece

3 CV risk assessment in dialysis patients. Does pre dialysis Blood pressure assessment really matter? Angela Wang, Hong Kong

Free Communication Session 2 + Mini LecturesPATIENT-REPORTED OUTCOME MEASURES - DOES IT IMPROVE HEALTH-CARE?

Chairs: Ray Vanholder, Belgium Marie Evans, Sweden

ML: Giovanni Tripepi, Italy PROMS CAN REPLACE TRADITIONAL OUTCOMES IN CLINICAL TRIALS? WHAT IS MORE IMPORTANT HEMOGLOBIN VALUE OR PATIENT'S TIREDNESS?

IMPROVED PREDICTION OF HOSPITALIZATION AND MORTALITY RISK BY ADDITION OF PATIENT REPORTED OUTCOME MEASURES (PROM) INTO RISK ALGORITHMS AMONG DIALYSIS PATIENTS Jasmine Ion Titapiccolo, Italy

PACE CKD: QUALITATIVE AND QUANTITATIVE INSIGHTS INTO THE ECONOMIC BURDEN OF CKD ON PATIENTS AND CARERS Juan Jose Garcia Sanchez, United Kingdom

Free Communication Session 17 + Mini LecturesPREDICTORS OF OUTCOME IN ANCA-ASSOCIATED VASCULITIS

Chairs: Zdenka Hruskova, Czech Republic Alexandre Karras, France

RENAL FUNCTION IS A MAJOR DETERMINANT OF B CELL REPOPULATION FOLLOWING RITUXIMAB INDUCTION IN ANCA-ASSOCIATED VASCULITIS Federica Mescia, Italy

BASELINE SOLUBLE IMMUNE CHECKPOINTS PREDICT RELAPSE RISK IN PR3-ANCA VASCULITIS FOLLOWING RITUXIMAB INDUCTION THERAPY Andreas Kronbichler, United Kingdom

SERUM AND URINE GALECTIN-9, IP-10 AND SIGLEC-1 AS BIOMARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS COMPARED TO ANCA-ASSOCIATED VASCULITIS: A LONGITUDINAL STUDY Safak Mirioglu, Turkey

HISTOPATHOLOGICAL AND CLINICAL OUTCOMES OF ANCA NEGATIVE VERSUS ANCA POSITIVE PAUCI-IMMUNE GLOMERULONEPHRITIS Lauren Floyd, United Kingdom

Free Communication Session 27 + Mini LecturesNEW TRENDS IN CKD

Chairs: Edwina Brown, United Kingdom Thimoteus Speer, Germany

ML: Jolanta Malyszko, Poland ANEMIA AND IRON UPDATE FROM KDIGO

DAILY PHOSPHORUS INTAKE, ITS SOURCE AND MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD STUDY Guobin Su, P.R. China

MATCHED.CONTROL STUDY ON APPLIED LONG-TERM ANTI-THROMBOTIC THERAPIES AND CLINICAL OUTCOME OF ATRIAL FIBRILLATION IN HD-PATIENTS BASED ON GERMAN NETWORK DATA. Karl August Brensing, Germany

APATHY ASSOCIATES WITH COGNITIVE DYSFUNCTION AND MORTALITY IN OLDER CKD PATIENTS. Carlijn Voorend, Netherlands

ML: Marion Pepin, France CLINICAL TESTING FOR COGNITIVE FUNCTION IN CKD PATIENTS

HALL S01 11:45-13:15 (CEST) HALL S03 11:45-13:15 (CEST)HALL S02 11:45-13:15 (CEST) VIRTUAL HALL 1 11:45-13:15 (CEST)

59TH


MAY 19-22, 2022

39


21 S

AT

59TH


MAY 19-22, 2022

Free Communication Session 22 + Mini LecturesTREATMENT FOR CKD

Chairs: Johannes Mann, Germany Kate Stevens, United Kingdom

ML: Nikolaus Marx, Germany THE ROLE OF SGLT2 INHIBITION IN HEART FAILURE: WHAT CAN NEPHROLOGISTS LEARN FROM CARDIOLOGISTS?

CHOLINESTERASE INHIBITORS AND KIDNEY FUNCTION DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA Hong Xu, Sweden

EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE ACCORDING TO BACKGROUND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKER DOSE Hiddo Lambers Heerspink, Netherlands

FINERENONE AND CANAGLIFLOZIN IN THE TREATMENT OF CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF FIDELIO-DKD AND CREDENCE David Cherney, Canada

MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN PATIENTS WITH RENAL INSUFFICIENCY AND ASSOCIATED RISK OF HYPERKALEMIA AND DEATH Sara Møller, Denmark


59TH


MAY 19-22, 2022

40


21 S

AT

Symposium 7.4A FAREWELL TO HYPERTENSIVE NEPHROSCLEROSIS

Chairs: Johannes F.E. Mann, Germany Francesca Mallamaci, Italy

1 Hypertensive nephropathy: a major roadblock to precision nephrology Sol Carriazo, Spain

2 Genetic phenocopies of hypertensive nephrosclerosis Alice Doreille, France

3 APOL1 associated disease spectrum Katalin Susztak, Hungary

59TH


MAY 19-22, 2022

Symposium 5.6CHOICE OF KRT

Chairs: Olof Heimbürger, Sweden Maria Haller, Austria

1 Transition between KRT modalities Antoine Lanot, France

2 Shared decision making in KRT Nicola Thomas, United Kingdom

3 Incremental hemodialysis Giorgina Piccoli, Italy

Symposium 3.3 NEW AVENUES IN LUPUS NEPHRITIS

Chairs: Eleni Frangou, Cyprus Vladimir Tesar, Czech Republic

1 Monogenic lupus nephritis. When to check, how to check, and what to do? Alexandre Belot, France

2 10 reasons why I rebiopsy my patients with lupus nephritis Iva Gunnarsson, Sweden

3 How to predict lupus nephritis non-invasively: lessons learned from machine learning and cross-species transcriptome analysis Eleni Frangou, Cyprus

Symposium 4.3 IS MICROBIOTA RESPONSIBLE FOR THE UREMIC TOXICITY?

Chairs: Peter Stenvinkel, Sweden Lucia Del vecchio, Italy

1 The kidney is responsible for toxins accumulation Griet Glorieux, Belgium

2 The microbiota is responsible for toxins production Sandra Wagner, France

3 Nutrients regulate the microbiota post translational activity and toxin production Wendy Garrett, USA

HALL PLENARY 15:00-16:30 (CEST) HALL N02 15:00-16:30 (CEST) HALL N03 15:00-16:30 (CEST)HALL N01 15:00-16:30 (CEST)

59TH


MAY 19-22, 2022

41


21 S

AT

59TH


MAY 19-22, 2022

Symposium 1.3 TUBULAR TRANSPORT

Chairs: Carsten Wagner, Switzerland Sandrine Florquin, Netherlands

1 Potassium channels controlling tubular functions Richard Warth, Germany

2 Mitochondrial function and diversity along the nephron Andrew Hall, Switzerland

3 Oxalate handling in health and disease-crosstalk gut and kidney Felix Knauf, Germany

Symposium 8.3CLINICAL ASPECTS OF AKI PREVENTION AND TREATMENT

Chairs: Claudio Ronco, Italy Jolanta Malyszko, Poland

1 The second hit hypothesis - what should we look for? Eric Hoste, Belgium

2 Fluids in the ICU - which is the wright one? Michael Joannidis, Austria

3 Identifying patients at high risk of in-hospital AKI Catalina Martin, Spain

Free Communication Session 10 + Mini LecturesGENETIC SCREENING FOR CHRONIC KIDNEY DISEASE

Chairs: Martin de Borst, Netherlands Albertien van Eerde, Netherlands

ML: Albertien Van Eerde, Netherlands GENETICS-FIRST APPROACH IMPROVES DIAGNOSTICS OF ESKD PATIENTS

GENOME-WIDE ASSOCIATION META-ANALYSIS IDENTIFIES NOVEL LOCI FOR KIDNEY FAILURE Peter van der Most, Netherlands

GENOMIC APPROACH OF THE UNDETERMINED KIDNEY DISEASE Thomas Robert, France

EXOME SEQUENCING OF THE ISRAELI DIALYSIS-TREATED PEDIATRIC POPULATION REVEALS MONOGENIC ETIOLOGY IN ~44% OF CASES Maayan Kagan, Israel

A CLINICAL WORKFLOW FOR SELECTION OF PATIENTS AND COST-EFFICIENT DIAGNOSIS OF GENETIC KIDNEY DISEASES Luigi Cirillo, Italy

Free Communication Session 31 + Mini LecturesRENOPROTECTIVE DRUGS IN KIDNEY TRANSPLANTATION - READY FOR PRIME TIME?

Chairs: Nine Knoers, Netherlands Mehmet Sukru Sever, Turkey

ML: Trond Jenssen, Norway IS THERE A ROLE FOR SLGT2 INHIBITORS IN THE TREATMENT OF PTDM?

SGLT2 INHIBITORS IN KIDNEY TRANSPLANTATION: A MULTICENTER STUDY Clara García Carro, Spain

VALIDATION OF AUTOMATED URINARY CHEMOKINE ASSAYS FOR NON-INVASIVE DETECTION OF KIDNEY TRANSPLANT REJECTION: A LARGE PROSPECTIVE COHORT STUDY. Elisabet Van Loon, Belgium

THE EFFECT OF SPIRONOLACTONE ON CALCINEURININHIBITOR INDUCED NEPHROTOXICITY - THE SPIREN TRIAL Line Aas Mortensen, Denmark

HALL S02 15:00-16:30 (CEST) HALL S03 15:00-16:30 (CEST)HALL S01 15:00-16:30 (CEST)HALL N04 15:00-16:30 (CEST)

59TH


MAY 19-22, 2022

42


21 S

AT

59TH


MAY 19-22, 2022

Free Communication Session 18 + Mini LecturesNEPHROTIC SYNDROME FROM CHILDHOOD TO ADULTHOOD

Chairs: Marina Vivarelli, Italy Arvind Bagga, India

ML: Matt Sampson, USA GWAS IN GLOMERULAR DISEASE AND ITS CONTRIBUTION TO THE UNDERSTANDING OF THE PATHOGENESIS AND IDENTIFICATION OF NEW THERAPEUTIC TARGETS

COMBINED PROTEOMIC ANALYSES OF RECURRENT IDIOPATHIC NEPHROTIC SYNDROME PLASMA AND PLASMA-TREATED HUMAN PODOCYTES Mario Ollero, France

CIRCULATING ANTI-RITUXIMAB ANTIBODIES DO NOT AFFECT RESPONSE TO RITUXIMAB IN STEROID-DEPENDENT NEPHROTIC SYNDROME Andrea Angeletti, Italy

LONG-TERM OUTCOME OF CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME Myriam Dao, France

ASSOCIATION OF PLA2R ANTIBODY EXPOSURE AND EGFR SLOPE IN PLA2R-RELATED MEMBRANOUS NEPHROLOGY: RESULTS FROM A COHORT OF 3982 ADULT CHINESE PATIENTS Wei-Bo Le, P.R. China


Free Communication Session 23 + Mini LecturesCOVID-19 AND OXYGEN

Chairs: Luuk Hilbrands, Netherlands Michelle Willicombe, United Kingdom

ML: Masaomi Nangaku, Japan OXYGEN BIOLOGY IN THE CKD PATIENTS

CEREBRAL OXYGENATION DURING EXERCISE ACROSS DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE Marieta Theodorakopoulou, Greece

IMPROVED IMMUNOLOGIC RESPONSE TO COVID-19 VACCINE WITH PROLONGED DOSING INTERVAL IN HEMODIALYSIS PATIENTS Mathias Haarhaus, Sweden

EFFECTIVENESS OF COVID-19 VACCINES IN A LARGE EUROPEAN HAEMODIALYSIS COHORT Paola Carioni, Italy

ML: Michelle Willicombe, United Kingdom COVID VACCINATION UPDATE IN KIDNEY DISEASE PATIENTS


59TH


MAY 19-22, 2022

43


21 S

AT

Symposium 5.5CKD-MBD IN ESKD – TRADITIONAL AND NOVEL APPROACHES

Chairs: Halima Resic, Bosnia and Herzegovina Ligia Petrica, Romania

1 Evaluation of bone fracture risk in CKD Hanne Skou Jorgensen, Denmark

2 Klotho and/or FGF23: ready to measure both? Marc Vervloet, Netherlands

3 VDR and CaSR activation as treatment options Mario Cozzolino, Italy

59TH


MAY 19-22, 2022

Symposium 6.2IMMUNOCOMPETENCE IN RENAL TRANSPLANTATION

Chairs: Umberto Maggiore, Italy Marta Crespo, Spain

1 Torque-teno virus and kidney transplantation: can we tailor immunosuppression? Gregor Bond, Austria

2 Steering transplant immunosuppression by virus-specific T Cells Thurid Ahlenstiel-Grunow, Germany

3 Cytomegalovirus after kidney transplantation in 2022: moving towards personalized prevention Rachel Hellemans. Belgium

4 How to improve the response to COVID-19 vaccination in kidney transplant recipients Luuk Hilbrands, Netherlands

Symposium 3.6 BRIDGING THE GAPS BETWEEN BASIC SCIENCE AND HUMAN TRIALS FOR KIDNEY HEALTH INTERVENTIONS

Chairs: Hans Joachim Anders, Germany Rosanna Coppo, Italy

1 Translational research – bridging the gaps between animal studies and human trials for kidney health interventions (drugs) Agnes Fogo, USA

2 Pathology of interferon-mediated damage Ingeborg Bajema, The Netherlands

3 Gene Expression as a Guide to the Development of Novel Therapies in Primary Glomerular Diseases Eleni Frangou, Cypru

Symposium 2.3 HOW TO OPTIMALLY PREVENT PROGRESSION IN ADPKD. Chairs: Roser Torra, Spain Albert Ong, United Kingdom

1 Lifestyle interventions Esther Meijern, Netherlands

2 How to improve tolerability of tolvaptan Ron Gansevoort, Netherlands

3 Updated ERA WGIKD / ERKNet position statement which ADPKD patients to prescribe tolvaptan Roman Muller, Germany

HALL N02 17:00-18:30 (CEST) HALL N03 17:00-18:30 (CEST)HALL N01 17:00-18:30 (CEST)HALL PLENARY 17:00-18:30 (CEST)

59TH


MAY 19-22, 2022

44


21 S

AT

Symposium 8.2AKI-CKD TRANSITION - IS IT INEVITABLE?

Chairs: Marlies Ostermann, United Kingdom Michael Joannidis, Austria

1 New Insights into Acute-on-Chronic Kidney Disease in Nephrology Patients: The CKD-REIN Study Aghilès Hamroun, France

2 Improving kidney tissue oxygenation to prevent AKI-CKD transition Kai-Uwe Eckardt, Germany

3 Post AKI monitoring - how to recognize progressive CKD? Vincenzo Cantaluppi, Italy

59TH


MAY 19-22, 2022

Symposium 7.5HUMAN URINE AS THE WINDOW OF RENAL DISEASE

Chairs: My Svensson, Norway Inga Arune Bumblyte, Lithuania

1 Non invasive biomarkers for Kidney fibrosis Benjamin D Humphrey, USA

2 Urine markers for systemic sclerosis in CKD Edward Stern, United Kingdom

3 The role of urinary ApoA-Ib in idiopati FSGS. Conxita Jacobs-Cachá, Spain

Free Communication Session 6 + Mini LecturesVARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM I

Chairs: Detlef Bockenhauer, United Kingdom Dominique Eladari, France

ML: Dominique Eladari, France KIDNEY INTERCALATED CELLS IN HEALTH AND DISEASE

THE B1 H+-ATPASE (ATP6V1B1) SUBUNIT IS REQUIRED FOR NON-TYPE A INTERCALATED CELL FUNCTION DURING ALKALOSIS Soline Bourgeois, Switzerland

PARIETAL EPITHELIAL CELLS ACTIVATION DURING GEMCITABINE-INDUCED NEPHROTOXICITY: COMMUNICATION WITH ENDOTHELIAL CELLS? Chloé Ben Ali, France

THE UREMIC TOXIN INDOXYL SULFATE IS AN ACTIVATOR OF CASPASE-4 BUT NOT OF CASPASE-1 IN MONOCYTE-LIKE THP-1 CELLS Christof Ulrich, Germany

SAFFRON-DERIVED BIOACTIVE MOLECULES AND THEIR IN-VITRO ACTIVITY ON KIDNEY AND BLADDER TUMORAL CELLS Arianna Bettiga, Italy

Free Communication Session 19 + Mini LecturesGENE AND CELL THERAPY COME OF AGE FOR THE NEPHROLOGIST

Chairs: Jonathan Barratt, United Kingdom Elena Levtchenko, Belgium

ML: Jonathan Barratt, United Kingdom CLINICAL APPLICATION OF MICRORNAS IN GLOMERULAR DISEASES

PHARMACOKINETICS AND PHARMACODYNAMICS OF LUMASIRAN: ANALYSIS OF FOUR CLINICAL STUDIES John Gansner, USA

LUMASIRAN FOR PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 WITH IMPAIRED KIDNEY FUNCTION: DATA FROM THE 6-MONTH ANALYSIS OF THE PHASE 3 ILLUMINATE-C TRIAL Jaap Groothoff, Netherlands

AN HDAC INHIBITOR ATTENUATES CRESCENTIC GLOMERULONEPHRITIS AND AVOID CHRONIC KIDNEY DISEASE ENHANCING PODOCYTE PROGENITOR DIFFERENTIATION Maria Elena Melica, Italy

ACUTE KIDNEY INJURY AND CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY IN HAEMATOLOGIC NEOPLASIAS. THE IMPORTANCE OF KIDNEY DISEASE. Juan León Román, Spain


59TH


MAY 19-22, 2022

45


21 S

AT

59TH


MAY 19-22, 2022

Free Communication Session 3 + Mini LecturesSEX DIFFERENCES IN NEPHROLOGY - DOES IT MATTER FOR PATIENT OUTCOME?Chairs: Juan Jesus Carrero, Sweden Maryvonne Hourmant, FranceML: Sofia Ahmed, Canada GENDER AND NEPHROLOGY

SEX DIFFERENCES IN THE RECOGNITION, MONITORING AND MANAGEMENT OF CHRONIC KIDNEY DISEASE IN HEALTH CARE Oskar Swartling, Sweden

THE IMPACT OF SEX ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN OLDER ADULTS WITH ADVANCED CHRONIC KIDNEY DISEASE: RESULTS FROM THE EQUAL STUDY THE IMPACT OF SEX ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN OLDER ADULTS WITH ADVANCED CHRONIC KIDNEY DISEASE: RESULTS FROM THE EQUAL STUDY Megan Astley, Netherlands

SEX DIFFERENCE IN COVID-19 MORTALITY RISK AMONG PATIENTS ON KIDNEY FUNCTION REPLACEMENT THERAPY Priya Vart, Netherlands

WOMEN IN NEPHROLOGY LEADERSHIP: A SURVEY BY THE SFNDT Sabine Karam, Lebanon


Free Communication Session 11 + Mini LecturesPEDIATRIC NEPHROLOGYChairs: Franz Schaeffer, Germany Rhuksana Shroff, United Kingdom

ML: Asaf Vivante, Israel CHILDHOOD CANCER AND RISK OF ESKD

A STUDY TO ASCERTAIN THE OPTIMUM STARTING DOSE OF SUBCUTANEOUS (SC) C.E.R.A. FOR MAINTENANCE TREATMENT OF ANAEMIA IN PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) ON DIALYSIS OR NOT YET ON DIALYSIS Bradley Warady, USA

EFFICACY OF LEVAMISOLE FOR MAINTAINING REMISSION AFTER THE FIRST FLARE OF STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDREN: THE NEPHROVIR-3 RANDOMIZED CONTROLLED TRIAL Claire Dossier, France

ASSOCIATIONS BETWEEN MATERNAL ANTENATAL SYSTEMIC GLUCOCORTICOIDS USAGE AND CHILDHOOD CHRONIC KIDNEY DISEASE Chien-Ning Hsu, Taiwan

KIDNEY TRANSPLANTATION IN CHILDHOOD-ONSET ANCA-ASSOCIATED VASCULITIS: OUTCOMES IN A MULTICENTRE COHORT Giorgio Trivioli, Italy

ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


The Nephrology Cookbook Project

Healthy Food for Healthy Kidneys

47

22SUN

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 13


SUNDAY - MAY 22, 2022 47

TARGETING MR OVERACTIVATION WITH FINERENONE: A NOVEL APPROACH TO KIDNEY AND CARDIOVASCULAR PROTECTION IN PATIENTS WITH CKD AND T2D

48

AGEING IN CKD 48

PREGNANCY AND THE KIDNEY 48

SUPPORTING NEEDS OF OLDER FRAIL PEOPLE CONSIDERING DIALYSIS 48

MECHANISMS OF HYPERTENSION REVISITED: IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT

49

RENAL TUBULAR CELL FUNCTION 49

WHERE ARE WE NOW IN THE HEMODIALYSIS VASCULAR ACCESS? 49

THE PROMISE OF CREATING KIDNEYS 49

OMICS AND KIDNEY OUTCOMES 50

NEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF GN 50

PLENARY LECTURE 3 - AWARDEES 51

NEPHROLOGY PEARLS 51

59TH


MAY 19-22, 2022

48

S C I E N T I F I C P R O G R A M M E

22 S

UN

22SUN

Symposium 4.10TARGETING MR OVERACTIVATION WITH FINERENONE: A NOVEL APPROACH TO KIDNEY AND CARDIOVASCULAR PROTECTION IN PATIENTS WITH CKD AND T2D

Chairs: Christoph Wanner, Germany Paola Fioretto, Italy

1 Welcome and introductions

2 Unmet need CKD in T2D: Targeting mineralocorticoid receptor (MR) overactivation David Cherney, Canada

3 FIDELITY - Cardiorenal outcomes across the spectrum of CKD in T2D George Bakris, USA

4 Safety and considerations for optimising patient outcomes Katherine Tuttle, USA

5 Implications of key subgroup analyses from the trial programme Peter Rossing, Danmark

6 Clinical consequences of the findings - UACR as a Cardiovascular and kidney outcomes risk factor Rajiv Agarwal, USA

7 Q&A

Symposium 4.5AGEING IN CKD

Chairs: Goce Spasovski, Republic Of North Macedonia Beatriz Fernandez Fernandez, Spain

1 Ageing biomarkers in CKD: time for rejuvenation? Katrien De Vusser, Belgium

2 The road to healthy ageing Paul Shiels, Scotland

3 Targeting the uremic phenotype in CKD: is food as medicine option? Denise Mafra, Scotland

Symposium 2.5 PREGNANCY AND THE KIDNEY

Chairs: Liz Lightstone, United Kingdom Jolanta Malysko, Poland

1 Renal and pregnancy outcomes in advanced CKD patients Liz Lightstone, United Kingdom

2 Effect of pregnancy on eGFR slope and predictors of pregnancy outcomes in kidney transplantation: a national cohort study Marleen C. van Buren, Netherlands

3 Adverse pregnancy outcomes and long-term maternal kidney disease Peter Barrett, Ireland

Symposium 5.4SUPPORTING NEEDS OF OLDER FRAIL PEOPLE CONSIDERING DIALYSIS

Chairs: Andrew Davenport, United Kingdom Liliana Garneata, Romania

1 Developing a supportive assisted CAPD programme Edwina Brown, United Kingdom

2 Why does cognitive function decline and what can be done about it Dawn F Wolfgram, USA

3 Benefits of conversations about ceilings of care Monika Lichodziejewska-Niemierko, Poland

HALL N02 08:30-10:00 (CEST) HALL N03 08:30-10:00 (CEST)HALL N01 08:30-10:00 (CEST)HALL PLENARY 08:30-10:00 (CEST)

59TH


MAY 19-22, 2022

49


22 S

UN

22SUN

Symposium 4.9MECHANISMS OF HYPERTENSION REVISITED: IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT

Chairs: Pieter Evenepoel, Belgium Dorothea Nitsch, United Kingdom

1 Fibromuscular dysplasia: from a rare disease to a frequent clinical suspicion? Alexandre Persu, Belgium

2 Renal denervation in patients with CKD: current evidence and future perspectives Roland Schmieder, Germany

3 Blood pressure variability in CKD: from diagnosis to treatment Jong Hyun Jhee, Korea

Free Communication Session 7 + Mini LecturesRENAL TUBULAR CELL FUNCTION

Chairs: Robert John Unwin, United Kingdom Giovanni Gambaro, Italy

ML: Soeren Lienamp, Switzerland REPROGRAMMING TUBULAR CELLS

PI3K/AKT/MTOR PATHWAY REGULATES RENAL EXPRESSION OF KLOTHO Aurora Pérez-Gomez, Spain

HUMAN ADULT RENAL PROGENITOR CELLS SECRETE IN THE KIDNEY VERY HIGH LEVELS OF THE ANTI-AGING PROTEIN KLOTHO SUSTAINED BY THE LONG NO-CODING RNA HOTAIR Angela Picerno, Italy

RENAL PROXIMAL TUBULES CB1 RECEPTOR MODULATES MTORC1 SIGNALING IN HEALTH AND DISEASE Liad Hinden, Israel

ML: Santiago Lamas, Spain MITOCHONDRIAL HOMEOSTASIS IN PROXIMAL TUBULAR CELLS

Free Communication Session 26 + Mini LecturesWHERE ARE WE NOW IN THE HEMODIALYSIS VASCULAR ACCESS?

Chairs: Ibeas JI, Spain Tamara Jemcov, Serbia

VON WILLEBRAND FACTOR: A CENTRAL REGULATOR OF ARTERIOVENOUS FISTULA MATURATION Suzanne Laboyrie, Netherlands

IN ASSESSING OF CARDIOPULMONARY RECIRCULATION IN HD PATIENTS Aleksei Zulkarnaev, Russia

ARTERIOVENOUS ACCESS AND OUTCOMES IN INCIDENT HEMODIALYSIS PATIENTS: IS FISTULA FIRST APPROACH STILL HOLDING? Natalia Alencar de Pinho, France

COVID-19 AND HD VASCULAR ACCESS: TROUBLES ARE COMING Aleksei Zulkarnaev, Russia

ECHOCARDIOGRAPHY: A PROMISING SCREENING AND MONITORING TOOL FOR CENTRAL VENOUS STENOSIS IN HEMODIALYSIS PATIENTS Ruoxi Liao, P.R. China

THE IMPACT OF VASCULAR ACCESS TYPES ON SURVIVAL IN HEMODIALYSIS: TIME FOR A SHIFT IN PARADIGM? A PROSPECTIVE COHORT STUDY. Rossella De Leonardis, Italy

Free Communication Session 12 + Mini LecturesTHE PROMISE OF CREATING KIDNEYS

Chairs: Marianne Verhaar, Netherlands Albert Ong, United Kingdom

ML Adrian Woolf, United Kingdom GROWING KIDNEYS: A PARTY TRICK OR REALITY?

REGENERATION OF NEPHRONS AND RENAL STROMA USING THE RENAL DEVELOPMENTAL ENVIRONMENT OF ANIMAL FETUSES Yatsumu Saito, Japan

GENERATION OF PATIENT-SPECIFIC HIPSC-PODOCYTES TO STUDY PHENOTYPE-SPECIFIC ALTERATIONS AND TEST THERAPEUTIC TARGETS EX VIVO Victoria Rose, Germany

CALIBRATION OF GTEX SAMPLES USING CURATED PRIMARY HUMAN KIDNEY TISSUES IMPROVES IDENTIFICATION OF MEDULLA-SPECIFIC GENE EXPRESSION PATTERNS Stefan Haug, Germany

HETEROZYGOUS VARIANTS IN KINASE DOMAIN OF NEK8 CAUSE AN AUTOSOMAL-DOMINANT CILIOPATHY Laura Claus, Netherlands


59TH


MAY 19-22, 2022

50


22 S

UN

22SUN

Symposium 4.7 OMICS AND KIDNEY OUTCOMES

Chairs: Luca De Nicola, Italy Lucile Mercadal, France

1 Genomics Cristian Pattaro, Italy

2 Proteomic Julie Klein, France

3 Metabolomic Belen Ponte, Switzerland

Free Communication Session 20 + Mini LecturesNEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF GN

Chairs: Ulf Panzer, Germany Lubka Roumenina, France

ML: Emmanuelle Plaisier, France ABOUT THE GBM AND ANTI-GBM DISEASE

AN EPIGENETICALLY-DRIVEN MECHANISM TRIGGERED BY VIRAL AND BACTERIAL RNA REGULATES THE IL-6 LEVELS IN IGA NEPHROPATHY Fabio Sallustio, Italy

MINERALOCORTICOID RECEPTOR DRIVES PARIETAL EPITHELIAL CELL ACTIVATION AND GLOMERULAR INJURY DURING CRESCENTIC GLOMERULONEPHRITIS Pierre-Louis Tharaux, France

ROLE OF FACTOR H AND ITS RELATED PROTEINS (FHR-1, FHR-2 FHR-5) IN ANCA-ASSOCIATED VASCULITIS. GENETIC AND LONGITUDINAL SEROLOGICAL STUDY. Gema Maria Fernandez Juarez, Spain

DEVELOPMENT OF A HIGH-THROUGHPUT IN VIVO DRUG SCREENING ASSAY USING A FSGS-LIKE ZEBRAFISH MODEL Maximilian Schindler, Germany


59TH


MAY 19-22, 2022

51


22 S

UN

22SUN

Plenary Lecture 3AWARDEESChairs: Christoph Wanner, Germany Orsolya Cseprekál, Hungary


Symposium 0.3NEPHROLOGY PEARLS

Chairs: Christoph Wanner, Germany Serhan Z. Tuglular, Turkey

1 Basic Science and Translational Nephrology Marianne Verhaar, Netherland

2 Epidemiology and Clinical Nephrology Kitty Jager, Netherland

3 ESKD and Dialysis G. Gambaro, Italy

4 Kidney Transplantation Andreas Kronbichler, United Kingdom


Translational Science Francesco Trepiccione, Italy

Basic Science Turgay Saritas, Germany

Clinical Science Jennifer Lees, United Kingdom

ETHICS

REGISTRY

GNC


ERAC European


SAB




ECC Electronic


NPPCNephrology


LEADING EUROPEAN NEPHROLOGY

Clinical Kidney Journal

LEADING EUROPEAN NEPHROLOGY

NEPHROLOGY DIALYSIS TRANSPLANTATION

Discover NDT, CKJ and NEPInternationally renowned scientific

and educational journals published by ERA

53

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE

MODERATED MINI ORAL, SESSION 1 54

QUICK FIRE 1-2-3, SESSION 1 55CONTENT &

DAILY INDEXMODERATED MINI-ORALS

& QUICK FIRE 1,2,3

FRIDAY - MAY 20, 2022 53


59TH


MAY 19-22, 2022

54

20 F

RI

M O D E R AT E D M I N I - O R A L S & Q U I C K F I R E 1 , 2 , 320FRI

MODERATED MINI ORAL, SESSION 1

Chair: Edoardo Melilli, Spain Emily McQuarrie, United Kingdom

CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT – A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL Katherine Tuttle, USA

MOVING MORE ASSOCIATES WITH REDUCED RISK OF CARDIOVASCULAR DISEASE AND DEATH ACROSS ALL STAGES OF CHRONIC KIDNEY DISEASE: A UK BIOBANK STUDY Kate Stevens, United Kingdom

MACHINE LEARNING-BASED PREDICTION OF MORTALITY AND RISK FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE DEVELOPED WITH DATA FROM 10.000 PATIENTS OVER 11 YEARS Jose Ibeas, Spain

RISK OF COMPLICATIONS AFTER PERCUTANEOUS NATIVE KIDNEY BIOPSY IN PATIENTS RECEIVING ANTI-PLATELET AGENTS Francesco Fontana, Italy

COST-ANALYSIS OF A CLINICAL WORKFLOW FOR DIAGNOSIS OF INHERITED KIDNEY DISEASES Luigi Cirillo, Italy

INTRADIALYTIC EXERCISE: A LARGE-SCALE NATIONWIDE IMPLEMENTATION STUDY Pedro Martins, Portugal

DIFFUSION-MRI PREDICTS DECLINE OF RENAL FUNCTION IN CKD AND KIDNEY ALLOGRAFT PATIENTS Lena Berchtold, Switzerland

SUPERB MICRO-VASCULAR IMAGING: AN INNOVATIVE ULTRASOUND TECHNIQUE FOR EARLY DETECTING OF RENAL DAMAGE Zaher Armaly, Israel

CHARACTERIZATION OF ADRENAL GLAND DERIVED MEDIATORS OF VASCULAR CALCIFICATION Shruti Bhargava, Germany

THE ASSOCIATION OF BETA-HYDROXYBUTYRATE AND KIDNEY FUNCTION DECLINE IN THE GENERAL POPULATION. RESULTS FROM THE PREVEND STUDY Martine Knol, Netherlands

LONG-TERM RENAL OUTCOMES AFTER ST-ELEVATION MYOCARDIAL INFARCTION TREATED BY PERCUTANEAOUS CORONARY INTERVENTION Marie Legras, France

MOLECULAR MECHANISMS OF VASCULAR AGING IN CHILDREN WITH CHRONIC KIDNEY DISEASE Maria Bartosova, Germany

IMPACT OF RENAL INSUFFICIENCY ON CHOICE OF RHYTHM OR RATE CONTROL IN ATRIAL FIBRILLATION AND SUBSEQUENT EFFECTS ON CARDIOVASCULAR AND MORTALITY OUTCOMES Zille Baumbach, Denmark

TIME TO IMPROVEMENT OF ITCH INTENSITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS TREATED WITH DIFELIKEFALIN Botond Csiky, Hungary

VISUALISING AND DIFFERENTIATING KIDNEY DISORDERS BY URINARY PEPTIDOMICS USING A MACHINE LEARNING APPROACH Justyna Siwy, Germany

PERFORMANCE OF CREATININE-BASED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN WHITE AND BLACK SUBJECTS FROM EUROPE, BRAZIL AND AFRICA Pierre Delanaye, Belgium

SELF-ADMINISTERED EXERCISE AND BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SUB STUDY OF RENEXC- A RANDOMIZED CONTROLLED TRIAL Vaida Petrauskiene, Swede

MINI-ORALS HALL 09:30-10:45 (CEST)

59TH


MAY 19-22, 2022

55

20 F

RI

M O D E R AT E D M I N I - O R A L S & Q U I C K F I R E 1 , 2 , 320FRI

QUICK FIRE 1-2-3, SESSION 1

Chair: Kate Stevens, United Kingdom Jennifer Lees, United Kingdom

POST-TRANSLATIONAL GUANIDINYLATION OF APOLIPOPROTEIN C3 (APOC3) IS ASSOCIATED WITH KIDNEY AND VASCULAR INJURY Vera Jankowski, Germany

RENAL FUNCTIONAL RESERVE AS A MARKER TO STRATIFY THE RISK OF KIDNEY INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. Nicoletta Mancianti, Italy

NON-INVASIVE DIAGNOSIS OF VANCOMYCIN-INDUCED ACUTE KIDNEY INJURY USING URINE MICROSCOPY Cédric Rafat, France

THE IMPACT OF PRE-TRANSPLANTATION NEPHRECTOMY ON QUALITY OF LIFE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Paul, Geertsema, Netherlands

THE NEED FOR ROUTINE NATIVE NEPHRECTOMY IN THE WORK-UP FOR A KIDNEY TRANSPLANTATION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS Paul Geertsema, Netherlands

PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE – PXL770 - FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Pascale Gluais Dagorn, France

ACUTE KIDNEY DISEASE IN THE OUTPATIENT SETTING: FROM BIG DATA PHENOTYPING TO BIOMARKER VALIDATION USING THE NGAL AND DNLITE-IVD103 TESTS Chin-Chi Kuo, Taiwan, R.O.C.

CLINICAL SIGNIFICANCE OF POST-OPERATIVE ACUTE KIDNEY DISEASE AFTER NON-CARDIAC SURGERY. Soie Kwon, Korea, Rep. of South

IMPACT OF COVID-19 PANDEMIC ON IN-HOSPITAL ACUTE KIDNEY INJURY EPIDEMIOLOGY AND OUTCOMES: A RETROSPECTIVE COHORT STUDY Pasquale Esposito, Italy

DEEP ANALYSIS OF THE AKI - CKD IN ALLOGENEIC STEM CELL TRANSPLANTATION - A BIG DATA APPROACH Nicole Brüder, Germany

EFFECT OF CANCER STAGE ON ADVERSE KIDNEY OUTCOMES IN PATIENTS WITH ADVANCED MELANOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS Qiyu Wang, USA

CLINICAL CHARACTERISTICS AND TRAJECTORY IN A NATIONAL COHORT OF VETERANS TREATED WITH CONSERVATIVE MANAGEMENT VS. DIALYSIS Yoko Narasaki, USA

INCREASED SENESCENT CELL BURDEN AND ALTERATIONS IN NRF2 PATHWAY DRIVE UREMIC VASCULAR CALCIFICATION IN HUMANS Sam Hobson, Sweden

FATTY ACID-ASSOCIATED ALBUMIN INDUCES PROLIFERATION AND SENESCENCE OF PROXIMAL TUBULAR CELLS Yoshifumi Kurosaki, Japan

RENAL AND MAJOR CLINICAL OUTCOMES AFTER NEPHRECTOMY IN PATIENTS WITH PRE-EXISTING CHRONIC KIDNEY DISEASE (ON-CKD STUDY) Maxime Schleef, France

INTRAVENOUS CYCLOPHOSPHAMIDE FOR HIGH-RISK PRIMARY PLA2R-POSITIVE MEMBRANOUS NEPHROPATHY Gabriel Stefan, Romania

SPARSENTAN, THE DUAL ENDOTHELIN ANGIOTENSIN RECEPTOR ANTAGONIST (DEARA), ATTENUATES ALBUMINURIA AND PROTECTS FROM THE DEVELOPMENT OF RENAL INJURY TO A GREATER EXTENT THAN LOSARTAN IN THE GDDY MOUSE MODEL OF IGA NEPHROPATHY; A 16-WEEK STUDY Hajime Nagasawa, Japan

MULTI-ANTIBODY COMPOSITION IN LUPUS NEPHRITIES: ISOTYPE PREVALENCE AND CLINICAL OUCOME Andrea Angeletti, Italy

PATIENTS WITH ALPORT SYNDROME FROM THE RADAR REGISTRY: A NATURAL HISTORY STUDY Shiguang Liu, USA

DEFICIENCY OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR EXACERBATES CBSA-UNDUCED MEMBRANOUS NEPHROPATHY IN MICE Tzu-Ming Jao, Taiwan, R.O.C.


TRADITIONAL AND DISEASE RELATED CARDIOVASCULAR RISK FACTORS IN ANCA-ASSOCIATED VASCULITIS: A PROSPECTIVE, TWO-CENTRE, OBSERVATIONAL COHORT STUDY Yosta Vegting, Netherlands

USE OF CORTICOSTEROIDS IN A NORWEGIAN COHORT OF PATIENTS WITH IGA NEPHROPATHY AND RAPID PROGRESSION TO END STAGE RENAL DISEASE Yngvar Lunde Haaskjold, Norway

IL33 EXERTS TOXICITY IN THE HEART AS SECRETED BY RENAL INFLAMMATION. Nans Florens, USA

INHIBITION OF THE KDM4C AND JMJD3 HISTONE DEMETHYLASES ALLEVIATES THE TUBULAR RENAL DAMAGE TRIGGERED BY ENDOPLASMIC RETICULUM STRESS. Paula Diaz-Bulnes, Spain

NO TRANSLOCATION OF INTACT INTESTINAL BACTERIA DURING INTERMITTENT DIALYSIS THERAPIES Paul A Rootjes, Netherlands

56

59TH


MAY 19-22, 2022

DAY AT A GLANCE

MODERATED MINI ORAL, SESSION 2 57

QUICK FIRE 1-2-3, SESSION 3 58CONTENT &

DAILY INDEXMODERATED MINI-ORALS

& QUICK FIRE 1,2,3

FRIDAY - MAY 20, 2022 53


21SAT

59TH


MAY 19-22, 2022

57

M O D E R AT E D M I N I - O R A L S & Q U I C K F I R E 1 , 2 , 321SAT

21 S

AT

MODERATED MINI ORAL, SESSION 2

Chair: Annette Bruchfeld, Sweden Maria Jose Soler, Spain

IMPACT OF THE INTERNAL PARATHYROID CLOCK ON THE REGULATION OF PARATHYROID GENE EXPRESSION. Søren Egstrand, Denmark

ROXADUSTAT IMPROVES RENAL OSTEODYSTROPHY BY DUAL REGULATING BONE REMODELING Luyao Li, P.R. China

EXOSOMES FROM ENDOTHELIAL CELLS TO SMOOTH MUSCLE CELLS INDUCE VASCULAR CALCIFICATION IN EARLY CHRONIC KIDNEY DISEASE Ruoxi Liao, P.R. China

ASSOCIATIONS OF HAEMOGLOBIN VALUES AND RATE OF CHANGES WITH MACE IN THE ASCEND-ND RANDOMISED CLINICAL TRIAL Ajay K. Singh, USA

ELEVATED DIALYSATE IL-6 CONCENTRATIONS ARE PROSPECTIVELY ASSOCIATED WITH IMPAIRED TLR-STIMULATED CYTOKINE RELEASE FROM PERITONEAL CELLS — A LONGITUDINAL COHORT STUDY Rebecca Herzog, Austria

C.E.R.A. (CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR – METHOXY POLYETHYLENE GLYCOL EPOETIN BETA) IN PAEDIATRIC DIALYSIS PATIENTS WITH ANAEMIA OF CHRONIC KIDNEY DISEASE:

REAL-WORLD EVIDENCE FROM THE IPDN AND IPHN REGISTRIES Franz Schaefer, Germany

A POLYGENIC RISK SCORE FOR REDUCED EGFR IS ASSOCIATED WITH ADVERSE EVENTS IN A CHRONIC KIDNEY DISEASE COHORT – THE GERMAN CHRONIC KIDNEY DISEASE STUDY Inga Steinbrenner, Germany

CHRONIC KIDNEY DISEASE IN PRIMARY CARE AND THE RISK OF CARDIOVASCULAR COMORBIDITY AND MORTALITY Rikke Borg, Denmark

IMPLICATIONS OF USING VARIOUS EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN THE GNC (NAKO) STUDY Jan Lipovsek, Germany

CARDIORENAL OUTCOMES ASSOCIATED TO ORAL ANTICOAGULANT USE IN PATIENTS WITH ATRIAL FIBRILLATION Faizan Mazhar, Sweden

MORTALITY DIFFERENCES BETWEEN MEN AND WOMEN WITH CHRONIC KIDNEY DISEASE IN THE IRISH HEALTH SYSTEM: THE NATIONAL KIDNEY DISEASE SURVEILLANCE PROGRAMME Matthew Laird, Ireland

CLUSTERS OF CHRONIC CONDITIONS ACROSS THE SPECTRUM OF KIDNEY FUNCTION: A NATIONWIDE COHORT STUDY Michael Sullivan, United Kingdom

CHRONIC KIDNEY DISEASE INDUCES ENDOTOXIN-RELATED ACTIVATION OF THE INNATE IMMUNE SYSTEM Sander Dejongh, Belgium

POTASSIUM INTAKE DOES NOT PREDICT HIGH SERUM POTASSIUM LEVELS IN HEMODIALYSIS DASH DIET CONSUMERS. Cristina Garagarza, Portugal

CALCIFICATION OF BRANCHES IS SUPERIOR TO ABDOMINAL AORTIC CALCIFICATION IN PREDICTING MORTALITY OF HEMODIALYSIS PATIENTS Wen Shi, P.R. China

GPR124 - A DRIVER OF FIBROTIC KIDNEY DISEASES Patrick Blank, Germany

CARDIOVASCULAR EVENTS IN PATIENTS WITH ANEMIA ASSOCIATED WITH NON–DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE: REGIONAL ANALYSIS OF PATIENTS NOT PREVIOUSLY TREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS IN THE PRO2TECT TRIAL Kai-Uwe Eckardt, Germany


59TH


MAY 19-22, 2022

58

M O D E R AT E D M I N I - O R A L S & Q U I C K F I R E 1 , 2 , 321SAT

21 S

AT

QUICK FIRE 1-2-3, SESSION 2

Chair: Dominique Guerrot, France Sourabh Sharma, India

SYSTEMIC THERAPY WITH A SINGLE-DOSE KIDNEY-TARGETED BIOENGINEERED VEGF CONSTRUCT IMPROVES STENOTIC KIDNEY HEMODYNAMICS IN EXPERIMENTAL RENOVASCULAR DISEASE Gene Bidwell, USA

KIDNEY FUNCTION AND THE RISK OF HEART FAILURE AMONG OLDER ADULTS: A PROSPECTIVE POPULATION-BASED COHORT STUDY Antonios Douros, Canada

AGE-SPECIFIC IMPACTS OF RISK FACTORS ON ALL-CAUSE MORTALITY IN DIALYSIS PATIENTS Takuhiro Moromizato, Japan

ASSOCIATIONS OF SERUM SODIUM WITH MORTALITY IN PATIENTS ON MAINTENANCE HEMODIALYSIS TREATMENT Jule Pinter, Germany

IDIOPATHIC NEPHROTIC SYNDROME AFTER 10 YEARS-OLD:IS SYSTEMATIC RENAL BIOPSY APPROPRIATE? Claire Dossier, France

EFFECT OF THE COMBINED USE OF MAGNESIUM ASPARTATE AND L-CARNITINE ON THE PROGRESSION OF HEART VALVE DISEASE AND ENDOTHELIAL DAMAGE IN DIABETIC HEMODIALYSIS PATIENTS Oleksandr Susla, Ukraine

CLINICAL OUTCOMES IN PATIENTS ON HEMODIALYSIS WITH CONGESTIVE HEART FAILURE Xinju Zhao, P.R. China

MODERATE-TO-SEVERE CKD-ASSOCIATED PRURITUS (CKD-AP) IS INDEPENDENTLY ASSOCIATED WITH WORSE HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG DIALYSIS PATIENTS. Luca Neri, Italy

KIDNEY INVOLVEMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: A COHORT STUDY OF 103 PATIENTS JustineSolignac, France

EXOME SEQUENCING OF ISRAELI DRUZE INDIVIDUALS ON DIALYSIS REVEALS COMMON AS WELL AS POPULATION SPECIFIC MONOGENIC ETIOLOGIES IN ~30% Omer Shlomovitz, Israel

BIALLELIC PATHOGENIC VARIANTS IN ROBO1 ASSOCIATE WITH SYNDROMIC CAKUT Marie Engesser, Germany

GENOME-WIDE STUDIES REVEAL FACTORS ASSOCIATED WITH CIRCULATING UROMODULIN AND ITS RELATIONS WITH COMPLEX DISEASES Yong Li, Germany

SGLT2 INHIBITION PROMOTES INTRINSIC KIDNEY REGENERATION BY CELLS OF THE RENIN LINEAGE Loïs van der Pluijm, Netherlands

DECLINE OF REGENERATIVE CAPACITY OF RENAL PROGENITORS AND PROGRESSIVE POLYPLOIDIZATION OF TUBULAR CELLS CONTRIBUTE TO KIDNEY PHYSIOLOGIC RESPONSE DURING AGING Giulia Antonelli, Italy

GLUT2 AS A KEY FACTOR IN THE PATHOGENESIS OF DIABETIC KIDNEY DISEASE Majdoleen Ahmad, Israel

EXPERIENCES OF BEING A LIVING KIDNEY-DONOR-PERCEIVED AND MEASURED STRESS LEVELS BEFORE AND AFTER KIDNEY DONATION Maria Eriksson Svensson, Sweden

HUMORAL IMMUNE RESPONSE OF THE ADDITIONAL CHADOX1 NCOV-19 VACCINE FOLLOWING A TWO-DOSE INACTIVATED WHOLE-VIRUS SARS-COV-2 VACCINATION IN PATIENTS ON DIALYSIS Rungthiwa Kitpermkiat, Thailand

CAPILLARY POINT-OF-CARE CREATININE TESTING IN KIDNEY DISEASE PATIENTS Sarah Rosset-Zufferey, Switzerland

A RARE CASE OF SECONDARY HAEMOLYTIC UREMIC SYNDROME AFTER ANTI-SARS-COV-2 VACCINATION. Andrea Spasiano, Italy

CHANGE IN THE LEVEL OF NFKBP65 GENE EXPRESSION IN THE MYOCARDIUM AND KIDNEYS OF WISTAR RATS AND SPONTANEOUSLY HYPERTENSIVE RATS (SHR) THAT RECEIVED DIET RICH IN NACL Mokhamad Khasun, Russia


RENAL OUTCOMES IN HIGH DOSE CISPLATIN IN LOCALLY ADVANCED SQUAMOUS CELL CANCER OF THE HEAD AND NECK: A MONOCENTRIC EXPERIENCE Francesco Trevisani, Italy

EX VIVO C5B9 DEPOSITION TEST AS A DIAGNOSTIC AND MONITORING TOOL FOR PRIMARY AND TRANSPLANTATION ASSOCIATED AHUS Conxita Jacobs Cachá, Spain

59

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 59


PD - SAFER AT HOME: GROWING AND MAINTAINING HOME DIALYSIS PROGRAMS

61

THE FUTURE OF ANEMIA OF CKD: WHERE ARE WE GOING? 61

THE FUTURE OF ANEMIA OF CKD: WHERE ARE WE GOING? 61

EMERGING TREATMENT OPTIONS IN CKD & T2D: ARE GLP-1 RAS NEXT? - A DISCUSSION

61

AN IMPORTANT RENAL BIOMARKER: PROTEINURIA 62

ENSURING OPTIMAL RAASI THERAPY IN PATIENTS WITH HYPERKALEMIA: AN INTERDISCIPLINARY APPROACH

62

INNOVATIONS FOR PATIENT-CENTERED CARE IN DIALYSIS 62

ADSORPTION: THE NEW FRONTIER FOR BLOOD PURIFICATION 62

WHAT’S NEW IN FSGS & IGAN: CLASSROOM TO CLINIC™ 63

LUPUS NEPHRITIS: CAN WE PRESERVE KIDNEY FUNCTION? CURRENT CHALLENGES AND PRACTICAL CONSIDERATIONS

64

TRANSFORMING CARE IN ANCA VASCULITIS (GPA/MPA): AN ALTERNATIVE APPROACH TO REDUCE RELAPSES AND GLUCOCORTICOID USE

64

OVERCOMING DSA BARRIERS TO TRANSPLANT 64

APPLYING GENETICS IN YOUR KIDNEY PRACTICE 64

PROTEINURIA IN FSGS AND IGA NEPHROPATHY & THE DUAL ROLE OF ET-1 AND ANG II

65

APOL1-MEDIATED KIDNEY DISEASE (AMKD): A GENETICALLY-DRIVEN PROTEINURIC GLOMERULAR NEPHROPATHY

65

60

20FRI

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 59


CLOSING THE LOOP WITH SGLT2 INHIBITORS FOR CKD MANAGEMENT 65

RETHINKING THE ROLE OF NEPHROLOGISTS IN PREVENTION OF CKD THE OPPORTUNITY OF EARLY RISK IDENTIFICATION

65

UNCOVERING GENETIC CAUSES OF CKD AND MANAGING PRIMARY HYPEROXALURIA TYPE 1: AN UPDATE ON RECENT ADVANCES

66

59TH


MAY 19-22, 2022

61

20 F

RI

I N D U S T RY S P O N S O R E D S Y M P O S I A20FRI

ORGANIZED BY

ISS 1.1PD - SAFER AT HOME: GROWING AND MAINTAINING HOME DIALYSIS PROGRAMS

Chair: Vladimir Tesar, Czech Republic

1 Introduction Vladimir Tesar, Czech Republic

2 Experience during Covid-19 Edwina Brown, United Kingdom

3 Remote Patient Management Annabel Boyer, France

4 Getting EU Health Systems to be Home centric Raymond Vanholder, Belgium

5 Q&A All

HALL N01 09:45-10:45 (CEST)

ISS 1.2THE FUTURE OF ANEMIA OF CKD: WHERE ARE WE GOING?

Chair: Sunil Bhandari, United Kingdom

1 Symposium welcome and objectives Sunil Bhandari, United Kingdom

2 The latest on the underlying mechanism Christoph Wanner, Germany

3 When to treat, why and challenges of management Kirsten Johansen, USA

4 Q&A All faculty moderated by Sunil Bhandari, United Kingdom

5 Closing remarks Sunil Bhandari, United Kingdom

HALL N02 09:45-10:45 (CEST)

ORGANIZED BY

ORGANIZED BY

ISS 1.3TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY IN IGA NEPHROPATHY AND C3 GLOMERULOPATHY: CLINICAL AND THERAPEUTIC PERSPECTIVES

Chair: Giuseppe Remuzzi, Italy Jürgen Floege, Germany

1 Welcome note Giuseppe Remuzzi Italy Jürgen Floege, Germany

2 A clinical perspective on the evolving therapeutic strategy for IgAN Smeeta Sinha, United Kingdom moderated by Jürgen Floege, Germany

3 C3G in the spotlight – a clinical and therapeutic overview Veronique Frémeaux-Bacchi, France Moglie Le Quintrec-Donnette, France moderated by Giuseppe Remuzzi, Italy

4 Audience Q&A All faculty moderated by Jürgen Floege, Germany

5 Closing note Giuseppe Remuzzi, Italy Jürgen Floege, Germany

HALL N03 09:45-10:45 (CEST)

ORGANIZED BY

ISS 1.4EMERGING TREATMENT OPTIONS IN CKD & T2D: ARE GLP-1 RAS NEXT? - A DISCUSSION

Chair: Peter Rossing, Denmark

1 Welcome and introduction (chair) Peter Rossing, Denkmark

2 The Changing Treatment Landscape for CKD in T2D - Presentation + Roundtable discussion (incl. Q&A) Maria Soler, Spain

3 Current Evidence for GLP-1 RAs for CKD in T2D Presentation + Roundtable discussion (incl. Q&A) Ofri Mosenzon, Israel

4 What might the future hold for GLP-1 RAs in CKD & T2D? Presentation + Roundtable discussion (incl. Q&A) Hiddo Heerspink, The Netherlands

5 Closing remarks Peter Rossing, Denmark

HALL N04 09:45-10:45 (CEST)

59TH


MAY 19-22, 2022

62

20 F

RI


ORGANIZED BY

ORGANIZED BY

ISS 1.5AN IMPORTANT RENAL BIOMARKER: PROTEINURIA

Chair: Noémie Jourde-Chiche, France

1 Introduction Noémie Jourde-Chiche, France

2 Proteinuria as a surrogate endpoint in clinical trials : Past and present Kieran McCafferty, United Kingdom

3 Other clinical trial endpoints used in nephrology Patrick Mark, United Kingdom

4 Q&A All faculty

5 Close Noémie Jourde-Chiche, France

HALL S01 09:45-10:45 (CEST)

ISS 1.6ENSURING OPTIMAL RAASI THERAPY IN PATIENTS WITH HYPERKALEMIA: AN INTERDISCIPLINARY APPROACH

Chair: David Wheeler, United Kingdom

1 Chair's Introduction David Wheeler, United Kingdom

2 Consequences of hyperkalemia on optimal RAASi therapy Lucia Del Vecchio, Italy

3 Challenges for primary care physicians in the treatment of hyperkalemia: importance of practical treatments David Wheeler, United Kingdom

4 Enabling long-term RAASi therapy in patients with hyperkalemia: The role of novel potassium binders Patrick Rossignol, France

5 Panel discussion, Q&A and close David Wheeler, United Kingdom

HALL S03 09:45-10:45 (CEST)

ORGANIZED BY

ORGANIZED BY

ISS 1.7INNOVATIONS FOR PATIENT-CENTERED CARE IN DIALYSIS

Chair: Len Usyvat, USA Christian Combe, France

1 Welcome and Introduction Len Usyvat, USA Christian Combe, France

2 Hemodialysis: New perspectives for reducing complexity in daily practice Jeroen Kooman, The Netherlands

3 Home Dialysis: Technologies for high-quality goal-directed home dialysis Neill Duncan, United Kingdom

4 Q&A Len Usyvat, USA Christian Combe, France

HALL S02 09:45-10:45 (CEST)

ISS 1.8 ADSORPTION: THE NEW FRONTIER FOR BLOOD PURIFICATIONChair: Claudio Ronco, Italy

1 Adsorption: The new frontier for blood purification Claudio Ronco, Italy

2 HA330/HA380 for Critical Patient Ilona Bobek, Hungary

3 HA130 for ESRD Patient Dimitrios Petras, Greece


59TH


MAY 19-22, 2022

63

20 F

RI


ORGANIZED BY

ISS 1.9

WHAT’S NEW IN FSGS & IGAN: CLASSROOM TO CLINIC™Chair: Sharon Adler, USA

1 Welcome, pre-symposium test & Chair’s opening remarks Sharon Adler, USA

2 Plenary 1 Pathogenesis, risk prediction, and the role of proteinuria in FSGS and IgAN Moin Saleem, United Kingdom Jonathan Barratt, United Kingdom

3 Plenary 2 Improving management of FSGS and IgAN: Current best practice and future therapies Moin Saleem, United Kingdom Jonathan Barratt, United Kingdom


4 Workshop 1 Quiz: Awareness and diagnosis of FSGS and IgAN Moin Saleem, United Kingdom Jonathan Barratt, United Kingdom

5 Workshop 2 Case studies: Management of FSGS and IgAN in practice Moin Saleem, United Kingdom Jonathan Barratt, United Kingdom

6 Q&A All

7 Chair’s close and post-symposium test Sharon Adler, USA

59TH


MAY 19-22, 2022

64

20 F

RI


ISS 1.13APPLYING GENETICS IN YOUR KIDNEY PRACTICE

Chair: Bertrand Knebelmann, France

1 Welcome Bertrand Knebelmann, France

2 APOL1 Nephropathy: From discovery to clinical applications David Friedman, USA

3 Alport Syndrome: From bench to bedside Rachel Lennon, United Kingdom

4 Discussion Bertrand Knebelmann, France

HALL N04 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.11TRANSFORMING CARE IN ANCA VASCULITIS (GPA/MPA): AN ALTERNATIVE APPROACH TO REDUCE RELAPSES AND GLUCOCORTICOID USE

Chair: Benjamin Terrier, France

1 Unmet medical need in AAV and patient burden Benjamin Terrier, France

2 First in class treatment targeting the complement system David Jayne, United Kingdom

3 Assessing kidney function and Glucocorticoids need: When – How - Why? Annette Bruchfeld, Sweden

4 Q&A Benjamin Terrier, France

HALL N02 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.12OVERCOMING DSA BARRIERS TO TRANSPLANT

Chair: Christophe Mariat, France

1 Welcome and Opening - Overcoming DSA Barriers to transplant Christophe Mariat, France

2 Equity to access to kidney transplant & the challenge of the highly sensitised patient Dominique Bertrand, France

3 Therapeutic strategies in HLA in kidney transplantation Umberto Maggiore, Italy

4 Q&A All faculty

HALL N03 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.10LUPUS NEPHRITIS: CAN WE PRESERVE KIDNEY FUNCTION? CURRENT CHALLENGES AND PRACTICAL CONSIDERATIONS

Chair: Liz Lightstone, United Kingdom

1 Welcome and introductory remarks Liz Lightstone, United Kingdom

2 How can we help to preserve kidney function in lupus nephritis? Hans-Joachim Anders, Germany

3 Discussion - specific to the 1st presentation All faculty

4 Targeted B-cell therapies in lupus nephritis: what do we know so far? Enrique Morales, Spain

5 Discussion - specific to the 2nd presentation All faculty

6 Closing remarks Liz Lightstone, United Kingdom

HALL N01 13:30-14:30 (CEST)

ORGANIZED BY

59TH


MAY 19-22, 2022

65

20 F

RI


ORGANIZED BY

ISS 1.17RETHINKING THE ROLE OF NEPHROLOGISTS IN PREVENTION OF CKD THE OPPORTUNITY OF EARLY RISK IDENTIFICATION

Chair: Christoph Wanner, Germany

1 Introduction - Barriers for preventing CKD in patients with diabetes: How can we do better? Christoph Wanner, Germany

2 Early screening and risk identification of CKD in patients with diabetes: Why is it so important? Rikke Borg, Denmark

3 Primary Care as gatekeeper in CKD: The need for collaboration with nephrologists Kamlesh Khunti, United Kingdom

4 Rethinking roles and responsibilities in prevention of CKD in diabetes Panel

HALL S02 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.15APOL1-MEDIATED KIDNEY DISEASE (AMKD): A GENETICALLY-DRIVEN PROTEINURIC GLOMERULAR NEPHROPATHY

1 APOL1-mediated kidney disease (AMKD): A genetically-driven proteinuric glomerular nephropathy Aude Servais, France

HALL S03 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.14PROTEINURIA IN FSGS AND IGA NEPHROPATHY & THE DUAL ROLE OF ET-1 AND ANG II

Chair: Pierre-Louis Tharaux, France

1 Welcome and Housekeeping Pierre-Louis Tharaux, France

2 Spotlight on IgA Nephropathy – Clinical Significance of Proteinuria Loreto Gesualdo, Italy

3 Spotlight on FSGS – Clinical Significance of Proteinuria Sian Griffin, United Kingdom

4 Evidence For the Dual Role of ET-1 and Ang II in Proteinuria and CKD Progression in IgA Nephropathy and FSGS Pierre-Louis Tharaux, France

5 Your Questions Answered – Panel Discussion and Q&A All chaired by Pierre-Louis Tharaux, France

HALL S01 13:30-14:30 (CEST)

ORGANIZED BY

ISS 1.16CLOSING THE LOOP WITH SGLT2 INHIBITORS FOR CKD MANAGEMENT

Chair: Kieran McCafferty, United Kingdom

1 Introduction Kieran McCafferty, United Kingdom

2 Why and how should we optimize care for patients with CKD? Adeera Levin, Canada

3 In which patients should we use SGLT2 inhibitors? Beatriz Fernandez Fernandez, Spain

4 Faculty Q&A All

5 Summary & close Kieran McCafferty, United Kingdom


59TH


MAY 19-22, 2022

66

20 F

RI


ORGANIZED BY

ISS 1.18UNCOVERING GENETIC CAUSES OF CKD AND MANAGING PRIMARY HYPEROXALURIA TYPE 1: AN UPDATE ON RECENT ADVANCES

Chair: Justine Bacchetta, France

1 Welcome & Introduction Justine Bacchetta, France

2 Role of Genetic Testing in the Diagnosis and Management of CKD Laurent Mesnard, France

3 Management of Primary Hyperoxaluria Type 1: What’s New? Sander Garrelfs, The Netherlands

4 Real-life Case Experience in PH1 Management Justine Bacchetta, France

5 Questions & Answers Justine Bacchetta, France


67

21SAT

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 59


PREVENTING CKD IN PATIENTS WITH DIABETES EXPLORING THE CURRENT AND FUTURE ROLE OF GLP-1RA

69

BLOOD PURIFICATION: APHERESIS, DIALYSIS AND BEYOND 69

MCO DELIVERING HDX THERAPY: IMPROVING CLINICAL AND ECONOMIC OUTCOMES IN THE REAL WORLD

69

A SHIFT IN FOCUS: INTERNATIONAL INSIGHTS INTO THE OPTIMAL MANAGEMENT OF CKD-MBD

69

LOOKING BEYOND K+ IN HYPERKALEMIA FOR CARDIO-RENAL PROTECTION

70

A GUTSY NEW APPROACH TO DELAY THE PROGRESSION OF IGAN 70

INNOVATIVE TREATMENT STRATEGIES FOR HAEMODIALYSIS AND HYPERTENSION

70

À LA CARTE HEMODIALYSIS FOR PATIENT: PMMA ADSORPTIVE MEMBRANE

70

KIDNEY DISEASE AND COVID-19: ADDRESSING CHALLENGES TO PROTECT THE VULNERABLE

71

NONSTEROIDAL MRAS: A NEW HOPE FOR IMPROVED CARDIORENAL OUTCOMES IN PATIENTS WITH CKD AND T2D

71

THE BURDEN AND MANAGEMENT OF SYMPTOMS IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON HAEMODIALYSIS: AN INSIGHT INTO CKD-ASSOCIATED PRURITUS

71

HIF-PH INHIBITION: SIMPLICITY THROUGH INNOVATION FOR ADULT PATIENTS WITH ANAEMIA OF CKD

71

MANAGING FEMALE PATIENTS WITH FABRY DISEASE – THE RELEVANCE OF THE XX FACTOR

72

68

21SAT

59TH


MAY 19-22, 2022

DAY AT A GLANCE



FRIDAY - MAY 20, 2022 59


DIAGNOSIS AND MANAGEMENT OF AHUS: TIME IS OF THE ESSENCE 72

HOW CAN THE MULTIDISCIPLINARY CARE IMPROVE THE PATIENTS’ JOURNEY IN INHERITED RARE DISEASES? THE IMPORTANCE OF NEPHROLOGIST AS COORDINATOR.

73

THE MULTIPLE FACES OF ANCA VASCULITIS 73

INTRODUCING NIPRO’S NOVEL SUPER HIGH FLUX SHARP CUT-OFF DIALYZER

74

59TH


MAY 19-22, 2022

69

I N D U S T RY S P O N S O R E D S Y M P O S I A21SAT

21 S

AT

ORGANIZED BY

ORGANIZED BY

ISS 2.1 PREVENTING CKD IN PATIENTS WITH DIABETES EXPLORING THE CURRENT AND FUTURE ROLE OF GLP-1RA

Chair: Johannes Mann, Germany

1 New insights and guidelines in managing patients with CKD and Diabetes: What are the challenges? Johannes Mann, Germany

2 Evolving science with GLP-1RA in CKD: What is relevant for nephrology? Filip Krag Knop, Denmark

3 GLP-1RA in clinical management of patients with CKD and diabetes: Which patients will benefit? Katherine Tuttle, USA

4 Discussion - Addressing the key challenges and opportunities Johannes Mann, Germany

HALL N01 09:45-10:45 (CEST)

ISS 2.2 BLOOD PURIFICATION: APHERESIS, DIALYSIS AND BEYOND

Chair: Luigi Vernaglione, Italy

1 Introduction Luigi Vernaglione, Italy

2 Vitamin E-interactive High Retention Onset (HRO) membranes: a new option for ESRD patients Monica Zanella, Italy

3 Lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia Christina Taylan, Germany

4 Rheopheresis approach in uremic patients with Peripheral Artery Disease and Calciphylaxis Thomas Robert, France

5 Discussion Luigi Vernaglione, Italy

HALL N02 09:45-10:45 (CEST)

ISS 2.3 MCO DELIVERING HDX THERAPY: IMPROVING CLINICAL AND ECONOMIC OUTCOMES IN THE REAL WORLD

Chair: Mario Cozzolino, Italy

1 Introduction Mario Cozzolino, Italy

2 Uremic toxins and inflammation Peter Stenvinkel, Sweden

3 Impact on Hospitalizations and CV events Jernej Pajek, Slovenia

4 Improving pts reported outcomes and post-dialysis recovery time Jarrin Penny, Canada

5 Q&A All

HALL N03 09:45-10:45 (CEST)

ORGANIZED BY

ISS 2.4A SHIFT IN FOCUS: INTERNATIONAL INSIGHTS INTO THE OPTIMAL MANAGEMENT OF CKD-MBD

Chair: Marianne Rix, Denmark

1 Welcome and introduction Marianne Rix, Denmark

2 How high is high enough? 25(OH)D adequacy in non-dialysis CKD-MBD patients James Wetmore, USA Jan Kielstein, Germany

3 Audience Q&A and discussion Marianne Rix, Denmark

4 Controlling serum phosphate levels: a focus on CKD patients on dialysis Jürgen Floege, Germany

5 Audience Q&A and discussion Marianne Rix, Denmark

6 Key takeaway from the panel and close Marianne Rix, Denmark

HALL N04 09:45-10:45 (CEST)

ORGANIZED BY

59TH


MAY 19-22, 2022

70


21 S

AT

ORGANIZED BY

ORGANIZED BY

ORGANIZED BY

ORGANIZED BY

ISS 2.5 LOOKING BEYOND K+ IN HYPERKALEMIA FOR CARDIO-RENAL PROTECTION (Independent, CME-accredited symposium) Chair: Claire Sharpe, United Kingdom

1 Introduction Claire Sharpe, United Kingdom

2 Balancing cardio-renal protection and hyperkalemia risk in CKD Pantelis Sarafidis, Greece

3 Hyperkalemia inpatient management and post-discharge: when should we use K+ binders? David Thomas, United Kingdom

4 How can we reduce the burden of hyperkalemia? What level of potassium should we strive for? Ellen Hoogeveen, The Netherlands Panel discussion and audience Q&A All

5 Close Claire Sharpe, United Kingdom

HALL S01 09:45-10:45 (CEST)

ISS 2.6A GUTSY NEW APPROACH TO DELAY THE PROGRESSION OF IGAN

Chair: Jonathan Barratt, United Kingdom

1 Intro Jonathan Barratt, United Kingdom

2 The role of intestinal mucosal immunity in the pathophysiology of IgA nephropathy Rosanna Coppo, Italy

3 The predictive value of proteinuria and eGFR as surrogate endpoints Richard A. Lafayette, USA

4 Emerging Modes of Treatment of IgA Nephropathy Vladimír Tesař, Czech Republic

5 Q&A session All speakers

HALL S03 09:45-10:45 (CEST)

ISS 2.7 INNOVATIVE TREATMENT STRATEGIES FOR HAEMODIALYSIS AND HYPERTENSIONChair: Roland Schmieder, Germany

1 Introduction & Objectives Roland Schmieder, Germany

2 Advances in Hypertension Treatment: Patient Considerations for Renal Denervation Flavio Ribichini, Italy

3 Transform AV Fistula Creation with Ellipsys™ Vascular Access System Robert Shahverdyan, Germany

4 Preserving AV Access: Extending Fistula Longevity with IN.PACT™ Admiral™ DCB Raphael Coscas, France

5 Patient-centric solutions for dialysis access Francesca D'Ascenzo, Italy

6 Patient-centric solutions for dialysis treatment Gaetano LaManna, Italy

7 Key learnings & Conclusion All

HALL S02 09:45-10:45 (CEST)

ISS 2.8À LA CARTE HEMODIALYSIS FOR PATIENT: PMMA ADSORPTIVE MEMBRANE

Chair: Laurent Juillard, France

1 Introduction Laurent Juillard, France

2 PMMA could be ”Hors-d'oeuvre" or Plat (principal)? Ikuto Masakane, Japan

3 PBUT and inflammation process in HD patients: possible role for Adsorptive Hemodiafiltration Paolo Fabbrini, Italy

4 Enhancing Immune Protection in HD patients: role of PMMA membrane. Giuseppe Castellano, Italy

5 Discussion Laurent Juillard, France


59TH


MAY 19-22, 2022

71


21 S

AT

ISS 2.13HIF-PH INHIBITION: SIMPLICITY THROUGH INNOVATION FOR ADULT PATIENTS WITH ANAEMIA OF CKD

Chair: Denis Fouque, France

1 Living with anaemia of CKD: the patient experience (Pre-recorded) Denis Fouque, France

2 The story so far: history of treatment and current guidelines Denis Fouque, France

3 HIF activation: a coordinated approach to the management of anaemia of CKD Danilo Fliser, Germany

4 HIF activation: a coordinated approach to the management of anaemia of CKD Sunil Bhandari, United Kingdom

5 Real-world: Patient case study experience (Pre recorded) Masaomi Nangaku, Japan

6 Q&A Denis Fouque, France

HALL N04 13:30-14:30 (CEST)

ISS 2.11NONSTEROIDAL MRAS: A NEW HOPE FOR IMPROVED CARDIORENAL OUTCOMES IN PATIENTS WITH CKD AND T2D

Chair: Patrick Rossignol, France

1 Welcome and Introduction Patrick Rossignol, France

2 CKD in T2D: How urgently do we heed the call for treatment? Jolanta Malyszko, Poland

3 Cardiorenal protection in patients with CKD and T2D: From FIDELIO-DKD to FIDELITY Roland Schmieder, Germany

4 Nonsteroidal MRAs in clinical practice: Whom to treat, when and how? George Bakris, USA

5 Summary and close Patrick Rossignol, France

6 Q&A All faculty

HALL N02 13:30-14:30 (CEST)

ISS 2.12THE BURDEN AND MANAGEMENT OF SYMPTOMS IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON HAEMODIALYSIS: AN INSIGHT INTO CKD-ASSOCIATED PRURITUS

Chair: Edwina Brown, United Kingdom

1 Welcome and introduction Edwina Brown, United Kingdom

2 Exploring symptom burden in haemodialysis patients Marc Vervloet, The Netherlands

3 Uncovering the complexities of CKD-aP Vincent Brandenburg, Germany

4 Evolving management horizons in CKD-aP Kam Kalantar-Zadeh, USA

5 Audience Q&A All

6 Summary and meeting close Edwina Brown, United Kingdom

HALL N03 13:30-14:30 (CEST)

ORGANIZED BY

ORGANIZED BY

ISS 2.10KIDNEY DISEASE AND COVID-19: ADDRESSING CHALLENGES TO PROTECT THE VULNERABLE

Chair: Philippe Getault, France

1 Opening remarks: The impact of COVID-19 on patients with kidney disease Philippe Gatault, France

2 Kidney disease and COVID-19: exploring challenges and unmet needs Claudio Ronco, Italy

3 Protecting the vulnerable: COVID-19 prevention strategies for high-risk patients Hugh Montgomery, United Kingdom

HALL N01 13:30-14:30 (CEST)

ORGANIZED BY ORGANIZED BY

59TH


MAY 19-22, 2022

72


21 S

AT

ORGANIZED BY

ORGANIZED BY

ISS 2.15DIAGNOSIS AND MANAGEMENT OF AHUS: TIME IS OF THE ESSENCE

Chair: Alberto Ortiz, Spain

1 Introduction Alberto Ortiz, Spain

2 aHUS, Causes and Effects of Delayed Diagnosis Alberto Ortiz, Spain

3 aHUS, Associated Conditions Muddy the Water Samir Parikh, USA

4 aHUS management, Navigating Muddy Waters Giorgia Comai, Italy

5 Q&A Panel discussion All

HALL S03 13:30-14:30 (CEST)

ISS 2.14MANAGING FEMALE PATIENTS WITH FABRY DISEASE – THE RELEVANCE OF THE XX FACTOR

Chair: Gabriel Choukroun, France

1 Welcome and introduction Gabriel Choukroun, France

2 Understanding the clinical heterogeneity in females with Fabry disease: the impact of genotype, phenotype and X-chromosome inactivation Aleš Linhart, Czech Republics

3 Challenging the myths and confronting the realities in the management of female patients with Fabry disease Roser Torra, Spain

4 Q&A and panel discussion Gabriel Choukroun, France

5 Conclusion and take-home messages Gabriel Choukroun, France

HALL S01 13:30-14:30 (CEST)

ISS 2.17THE MULTIPLE FACES OF ANCA VASCULITIS

Chair: Hermann Haller, Germany

1 Introdcution Hermann Haller, Germany

2 Remission and relapse in ANCA-associated vasculitis: What does success look like? Noémie Jourde-Chiche, France

3 ANCA vasculitis from a different angle: Ear and nose involvement in a patient with AAV Marcos Martinez Del Pero, United Kingdom

4 What we need to know about central nervous involvement in ANCA vasculitis Bernhard Hellmich, Germany

5 Q&A Hermann Haller, Germany


ISS 2.16HOW CAN THE MULTIDISCIPLINARY CARE IMPROVE THE PATIENTS’ JOURNEY IN INHERITED RARE DISEASES? THE IMPORTANCE OF NEPHROLOGIST AS COORDINATOR.

Chair: Francesco Emma, Italy

1 Welcome and introduction Diego Ardigò, Italy

2 Nephropathic Cystinosis and Fabry Disease different approach and management: from diagnosis to therapeutic decision and follow-up Francesco Emma, Italy Antonio Pisani, Italy

3 Multidisciplinary management of Fabry Disease: key challenges and best practice Antonio Pisani, Italy

(Q&A moderated by Diego Ardigò, Italy)

4 Multidisciplinary management of Nephropathic Cystinosis disease: key challenges and best practice Myriam Dao, France (Q&A moderated by Francesco Emma, Italy)

5 Closing and remarks Francesco Emma, Italy

HALL S02 13:30-14:30 (CEST)

ORGANIZED BYORGANIZED BY

59TH


MAY 19-22, 2022

73


21 S

AT

ISS 2.18INTRODUCING NIPRO’S NOVEL SUPER HIGH FLUX SHARP CUT-OFF DIALYZER

Chair: Andrew Davenport, United Kingdom

1 Welcome and introduction Andrew Davenport, United Kingdom

2 Super high flux dialyzers and their associated survival in dialysis patients Abe Masanori, Japan

3 The impact of middle molecule uremic toxins on the clinical outcomes of dialysis patients Vincenzo Panichi, Italy

4 Evaluation and comparison of Elisio-HX versus HD, HDx and HDF dialyzers Francisco Maduell, Spain

5 Discussion Andrew Davenport, United Kingdom


ORGANIZED BY

Speakers• Professor David Wheeler, Chair

• Professor Patrick Rossignol

• Dr Lucia Del Vecchio

Ensuring optimal RAASi therapy in patients with hyperkalemia: An interdisciplinary approachFriday, May 20, 2022 09:45–10:45 CEST

Room S03

Document ID: FR-PAT-2200005; Date of preparation: March 2022. This industry symposium is sponsored and organized by Vifor Pharma. The ERA assumes no responsibility for the information published in this document.

• New CV data release - Thursday 19 May at 08:00 –12:45 CKD anaemia mini-oral session

• ERA Symposium - Saturday 21 May at 13.30 HIF-PH inhibition: Simplicity through innovation for patients with anaemia of CKD

• Discover more at booth D-360

New EVRENZO harnesses the HIF pathway2,3 to mimic the effects of hypoxia3 at high altitude

References

1. Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266. 2. EVRENZO EMA SmPC, 2021. 3. Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.

CKD, chronic kidney disease; HIF, hypoxia-inducible factor; HIF-PHI, hypoxia-inducible factor prolyl-hydroxylase inhibitor.

EVZ_2022_0038_ABC | April 2022 Date of Expiry: June 2022Astellas and the flying star logo are registered

trademarks of Astellas Pharma Inc.

FIRST-IN-CLASS HIF-PHI1

IN THE EU, EVRENZO (ROXADUSTAT) IS INDICATED FOR TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD)2

THIS INFORMATION IS INTENDED FOR INTERNATIONAL HEALTHCARE PROFESSIONALS

For more information, please consult the complete product information for EVRENZO (EMA). To access it, please scan the QR code or visit https://www.ema.europa.eu/en/documents/ product-information/evrenzo-epar-product-information_en.pdf.

EVREN3621_Evrenzo_Press_ad_ERA_v3.indd 1EVREN3621_Evrenzo_Press_ad_ERA_v3.indd 1 12/04/2022 09:1412/04/2022 09:14

Intended for HCPs only. Prescribing information for all GSK products discussed will be available at this symposium. ©2022 GSK group of companies. All rights reserved. | PM-FR-BEL-WCNT-220001 Date of preparation: April 2022

Lupus nephritis: can we preserve kidney function?

Current challenges and practical considerations

SEE YOU AT OUR SYMPOSIUM

Friday, May 20 13:30-14:30 CESTLocation: Room N01 Symposium available in person and livestreamed

Join us at our symposium to hear from international experts:

Chair: Professor Liz Lightstone Speakers: Professor Hans-Joachim Anders

Professor Enrique Morales

Topics will include: • Key considerations in lupus nephritis and preserving kidney function • Challenging case studies • Multidisciplinary approaches to improve long-term patient outcomes

Novartis-sponsored symposium (Live)

FUSE MLR ID: 204324 | Approval April 2022

Novartis Pharma AG© 2022 Novartis Pharma AG, CH-4002 Basel, Switzerland

Novartis is committed to patients living with complement-mediated kidney diseases, to bring transformative medicines that can potentially slow disease progression and extend dialysis-free life in these patients.

9:45 Welcome noteCo-chairs:Giuseppe Remuzzi, (Italy), Jürgen Floege, (Germany)

9:50 A clinical perspective on the evolving therapeutic strategy for IgAN Smeeta Sinha, (UK) Moderated by: Jürgen Floege, (Germany)

10:05 C3G in the spotlight – a clinical and therapeutic overviewVeronique Frémeaux-Bacchi, (France), Moglie Le Quintrec-Donnette, (France)Moderated by: Giuseppe Remuzzi, (Italy)

10:30 Live audience Q&AAll facultyModerated by: Jürgen Floege, (Germany)

10:40 Closing noteCo-chairs

Agenda

Targeting the alternative complement pathway in IgA nephropathy and C3 glomerulopathy: clinical and therapeutic perspectivesFriday, 20 May 2022 | 09:45–10:45 CEST | ERA Congress 2022Paris Expo Porte de Versailles, Paris, France Hall N03

© 2022 Travere Therapeutics, Inc. All rights reserved. April 2022 – MA-SP-21-0054

In IgA nephropathy and FSGS

Be Proactive Against Proteinuria

LowerProteinuria.com

See you next year in Milan

Save the dateStockholm 2024

CONGRESS - European Renal Association

Documents